

The Extra-Islet Pancreas Supports Autoimmunity in Human Type 1 Diabetes

Barlow, G.L.^{1,2,†}, Schürch, C.M.^{2,4}, Bhate, S.S.², Phillips, D.², Young, A.^{3,6,7}, Dong, S.^{3,5}, Martinez, H.A.¹, Kaber, G.¹, Nagy, N.¹, Ramachandran S.¹, Meng, J.¹, Korpos E.⁹, Bluestone, J.A.^{†,8}, Nolan, G.P.^{†,2}, Bollyky, P.L.^{†,‡,1}

† Corresponding Author

‡ Lead Contact

Affiliations:

1. Division of Infectious Diseases and Geographic Medicine, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, USA
2. Department of Pathology, Stanford University School of Medicine, Stanford, CA 94305, USA
3. Diabetes Center, University of California San Francisco, San Francisco, CA 94143, USA
4. Department of Pathology and Neuropathology, University Hospital and Comprehensive Cancer Center, Tübingen, Germany
5. Sean N. Parker Autoimmune Research Laboratory and Diabetes Center, University of California San Francisco, San Francisco, CA, USA
6. Huntsman Cancer Institute, University of Utah Health Sciences Center, Salt Lake City, UT 84112, USA
7. Department of Pathology, University of Utah School of Medicine, Salt Lake City, UT 84112, USA
8. Sonoma Biotherapeutics, South San Francisco, CA 94080 USA
9. Institute of Physiological Chemistry and Pathobiochemistry and Cells-in-Motion Interfaculty Center, University of Muenster, Germany

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Paul Bollyky (pbollyky@stanford.edu).

36 **Abstract**

37 In autoimmune Type 1 diabetes (T1D), immune cells infiltrate and destroy the islets of
38 Langerhans – islands of endocrine tissue dispersed throughout the pancreas. However, the
39 contribution of cellular programs outside islets to insulinitis is unclear. Here, using CO-Detection
40 by indEXing (CODEX) tissue imaging and cadaveric pancreas samples, we simultaneously examine
41 islet and extra-islet inflammation in human T1D. We identify four sub-states of inflamed islets
42 characterized by the activation profiles of CD8⁺T cells enriched in islets relative to the surrounding
43 tissue. We further find that the extra-islet space of lobules with extensive islet-infiltration differs
44 from the extra-islet space of less infiltrated areas within the same tissue section. Finally, we
45 identify lymphoid structures away from islets enriched in CD45RA⁺ T cells – a population also
46 enriched in one of the inflamed islet sub-states. Together, these data help define the
47 coordination between islets and the extra-islet pancreas in the pathogenesis of human T1D.

48
49
50

51 **Keywords:** Type 1 Diabetes; Insulinitis; Autoimmunity; Multiplexed Imaging; CODEX; Systems
52 Immunology; Tissue Architecture

53 Main

54 In Type 1 diabetes (T1D), insulin-producing β -cells are killed by islet-infiltrating immune cells in a
55 process called “insulinitis”. T1D results in a critical requirement for exogenous insulin and affects
56 over eight million individuals world-wide with an estimated 0.5 million new diagnoses each year
57 (Gregory et al. 2022).

58 Recently, the first immunotherapy for delaying T1D onset, teplizumab (a human anti-CD3
59 monoclonal antibody) was approved by the US Food and Drug Administration (Hirsch 2023).
60 However, this treatment and other immunotherapies help only a small fraction of patients and
61 are significantly less effective after patients progress to overt T1D (Herold et al. 2013; Perdigoto
62 et al. 2019; Herold et al. 2019; Pescovitz et al. 2009; Orban et al. 2011; 2014; Bluestone, Buckner,
63 and Herold 2021). A better understanding of T1D pathogenesis is essential to building on this
64 progress.

65 One of the challenges of studying human T1D pathology is the availability of suitable tissue
66 samples. Obtaining pancreatic biopsies raises the risk of surgical complications and the
67 progressive nature of T1D would necessitate serial, longitudinal studies over time, which is
68 prohibitive (Krogvold et al. 2014). Fortunately, the Juvenile Diabetes Research Foundation (JDRF)
69 Network for Pancreatic Organ Donors with Diabetes (nPOD) have provided human pancreatic
70 tissues from cadaveric donors for this study (Campbell-Thompson et al. 2012; Pugliese et al.
71 2014). nPOD has enabled substantial progress towards characterizing the pathology of human
72 T1D (Wilcox et al. 2016; Arif et al. 2014; Leete et al. 2016; Martino et al. 2015; Korpos et al. 2021).

73 Our understanding of key features of human T1D pathology remains limited. Although the
74 cellular composition of insulinitis, inflammation specifically of the islets, has been studied
75 extensively, this has been done in separate studies looking at different tissue sections, prohibiting
76 an understanding of how the numerous cellular programs in insulinitis are coordinated throughout
77 disease. This was recently addressed using Imaging Mass Cytometry (IMC), which uncovered
78 alterations in β -cell phenotypes, immune composition, vascular density, and basement
79 membrane (Damond et al. 2019; Wang et al. 2019). However, these studies did not deeply
80 phenotype islet-infiltrating CD8⁺T cells, believed to be major driver of β -cell elimination.

81 Recently, intriguing differences in the extra-islet spaces of T1D and healthy controls have been
82 reported. First, the abundance of multiple types of immune cells outside islets are increased in
83 T1D patients compared to non-T1D controls (Rodriguez-Calvo et al. 2014; Campbell-Thompson,
84 Rodriguez-Calvo, and Battaglia 2015; Bender et al. 2020). Second, HLA-DR expression is increased
85 on ductal cells in T1D tissue donors, hinting at a functional link with CD4⁺T cells (Fasolino et al.
86 2022). Third, peri-insulinitis, the accumulation of immune cells outside islets, is observed in tissues
87 from patients with T1D (Korpos et al. 2013), indicating that not all T cells enter the pancreas
88 directly via islet microvasculature (Savinov et al. 2003). Fourth, in human T1D, but less so in most
89 animal models, islets in different regions of the pancreas are infiltrated at strikingly different
90 rates for reasons that are unknown (In’t Veld 2014). This suggests that the extra-islet
91 compartment could be responsible by governing the targeting of islets. Finally, tertiary lymphoid
92 structures (TLS) – dense aggregates of lymphoid cells indicative of local immune activation – are
93 observed outside islets in T1D patients (Korpos et al. 2021).

94 In summary, analyzing both compartments simultaneously could help identify how these extra-
95 islet factors influence islet pathogenesis. However, to date, multiplexed imaging studies have
96 only examined islets. A comprehensive, spatially resolved cellular analysis of both compartments
97 in T1D is lacking.

98 Here, we investigated the islet and extra-islet pancreas together. We used CO-Detection by
99 indexing (CODEX) with an antibody panel targeting 54 antigens to samples from a cohort of T1D
100 patients with insulinitis as well as non-T1D individuals with and without islet-specific
101 autoantibodies (AA- and AA+ respectively) obtained through the JDRF nPOD program. We
102 analyzed approximately 2000 islets and broad swaths of the extra-islet tissue to evaluate local
103 and distal spatial architecture. We then used pseudotime analysis to characterize insulinitis sub-
104 states based on the activation states of islet-infiltrating CD8⁺T cells. We further investigated the
105 cellular changes in niches and lobules beyond islets. Our results implicate both the islet
106 microenvironment and inflammation at distal sites within the pancreas in the progression of
107 insulinitis.

108 **Cohort curation, image acquisition, and cell annotation**

109 The JDRF nPOD is a national registry of cadaveric pancreases donated by T1D patients that has
110 transformed the ability of researchers to investigate the pathways underlying the progression of
111 human T1D (Campbell-Thompson et al. 2012; Pugliese et al. 2014). Insulinitis is present in only a
112 small fraction of T1D cases, including nPOD's (In't Veld 2011; Atkinson and Mirmira 2023).
113 Although nPOD has close to 200 T1D cases, at the time of our study, nPOD had only 17 with
114 documented insulinitis. For some of these 17, tissues had been heavily sectioned and the current
115 tissue blocks did not still contain insulinitis. AA+ and T1D cases were selected by performing triple-
116 immunohistochemistry for Insulin, Glucagon, and CD3. T1D and AA+ cases that had CD3+ staining
117 in islet or peri-islet spaces and tissue still available were selected for our study. The final cohort
118 included two AA+ cases, eight T1D cases, and three non-T1D controls. Given that insulinitis is not
119 detected in non-T1D cases (Bruggeman et al. 2021), the blocks from controls were selected
120 randomly. The T1D cases varied in the time between diagnosis and death from 0 years (diagnosed
121 at death) to 6 years (Figure 1.A, left). The causes of death were mostly unrelated to T1D
122 complications (Supplemental Table 1). Therefore, the time since diagnosis is not a reflection of
123 the severity or aggressiveness of the individual's disease.

124 Large regions averaging 55 mm² were imaged with CODEX as previously described (Schürch et al.
125 2020; Phillips, Matusiak, et al. 2021; Hickey et al. 2021). Regions were selected to capture islets
126 and the surrounding region simultaneously (Figure 1.A, center and right). CellSeg was used to
127 segment cell nuclei and quantify marker expression from CODEX images as previously described
128 (Lee et al. 2022). In total, our dataset consisted of 7.0x10⁶ cells across all donors (ranging from
129 3.0x10⁵ to 9.8x10⁵ cells per donor). Twenty-one cell types were identified with Leiden clustering
130 and manual merging and visualized using Uniform Manifold Approximation and Projection
131 (UMAP) (Figure 1.B, Supplemental Table 2). Endocrine cells were manually gated from UMAP
132 embeddings derived from Proinsulin, Glucagon, and Somatostatin to identify b-cells, a-cells, and
133 d-cells respectively. Immune cells were sub-clustered with the Leiden algorithm using immune-
134 specific markers (Figure 1.C, Supplemental Table 2). To verify the accuracy of our annotations,

135 we overlaid labelled data onto the original images (Supplemental Figure 1.A). Of note, we could
136 not accurately identify macrophage subsets or distinguish dendritic cells from macrophages due
137 to the panel design, complex combinations of co-expression, and the difficulty in segmenting and
138 quantifying markers on myeloid populations due to their morphology. Therefore, we refer to this
139 cluster as “macrophage/DCs” In addition, we identified a cell population that could not be
140 definitively annotated, expressing high levels of CD45, CD69, Granzyme-B, and CD44,
141 intermediate levels of CD16, S100A6, Galectin-3, and Hyaluronan, but not expressing CD3, CD20,
142 CD56, CD57, CD15, or MPO. We confirmed from the raw images that CD3, CD4, and CD8 were
143 not internalized, indicating activation, nor did these cells express other T cell activation markers
144 CD45RA, CD45RO, PD-1, or LAG-3 (Figure 1.C, Supplemental Figure 1A, bottom right). This
145 population could represent a type of innate lymphoid cell (Dalmas et al. 2017) and was labeled
146 “Granzyme-B⁺/CD3⁻”.

147 **Islet- and extra-islet regions are altered in T1D**

148 We first sought to identify cellular changes in T1D within islets specifically. Previous reports
149 observed that insulin-containing islets are significantly more common in recent-onset T1D cases
150 than cases with diabetes durations of greater than one year (In’t Veld 2011; Campbell-Thompson
151 et al. 2016; Richardson and Pugliese 2022). Similarly, we found that samples from patients who
152 had been diagnosed with T1D for 0-2 years had significantly reduced β -cell frequencies compared
153 to non-T1D controls. Furthermore, samples from subjects with disease durations of 5-6 years had
154 minimal remaining β -cell mass (Figure 1.D). Whereas one AA+ case had β -cell mass comparable
155 to those of cases with disease duration of 0-2 years, the other AA+ case was comparable to non-
156 T1D controls (Figure 1.D). The total islet area imaged was comparable across all donors
157 (Supplemental Figure 1.B).

158 Next, we investigated how the abundances of non-endocrine cell types inside islets differed
159 across donors. We performed Principal Component Analysis (PCA) on the donors using the
160 frequencies of non-endocrine cell types located in islets. Donors were clearly separated into two
161 groups by the first two principal components; one group included all T1D cases and one AA+ case
162 and the second included all non-T1D cases and the other AA+ case (Figure 1.E). In this analysis,
163 we did not consider β -cells, α -cells, and δ -cells. Thus, donors were stratified by disease duration
164 strictly according to the abundances of immune and other pancreatic, non-endocrine cell types
165 in the islets.

166 We next considered only cells located outside islets. Again, donors were clearly separable by the
167 first two principal components (Figure 1.F). The first principal component separated cases with
168 times since diagnosis between 0-2 years from non-T1D, AA+, and cases with diabetes durations
169 of 5-6 years (Figure 1.F). The second principal component separated cases with diabetes
170 durations of 5-6 years from the rest (Figure 1.F). Therefore, both the islet and extra-islet spaces
171 of T1D and non-T1D cases were distinct.

172 Many cell types were increased in T1D cases with times since diagnosis of 0-2 years relative to
173 non-T1D controls (Supplemental Figure 1C). In T1D cases with times since diagnosis of 5-6 years,
174 the abundance of different cell types either remained higher than non-T1D controls or returned
175 to baseline (Supplemental Figure 1.C). This trend was present in both islet and extra-islet regions.

176 These data demonstrate that the immune activity between the islet and extra-islet
177 compartments are coordinated.

178 **Pseudotemporal reconstruction of islet pathogenesis** 179 **identifies a conserved trajectory of insulinitis**

180 In human T1D, β -cell destruction does not occur simultaneously across all islets and even
181 neighboring islets can be at different stages of destruction (In't Veld 2011; 2014; Damond et al.
182 2019). We therefore used pseudotime analysis to infer the most likely progression of a single islet
183 through disease space (Damond et al. 2019). To develop a pseudotemporal map, we quantified
184 the cellular composition of each islet, including cells within 20 μ m of the islet's boundary, and
185 applied the pseudotime algorithm PArtition-based Graph Abstraction (PAGA) (Figure 2.A; Figure
186 2.B), (Wolf et al. 2019). PAGA was selected because it is a high-performing algorithm able to
187 identify multiple trajectories, if they exist, while making minimal assumptions about the true
188 structure (Saelens et al. 2019).

189 Displayed in Figure 2.B is the PAGA force-directed layout where each point represents an islet.
190 Each islet's color reflects the pseudotemporal distance from the centroid of non-T1D islets. As
191 expected, the islets from different donor groups (no T1D, AA+, T1D) had different distributions
192 across the PAGA map (Figure 2.C). In the PAGA map, a continuum is apparent from islets
193 abundant in insulin-expressing β -cells on the left of the map to islets depleted in β -cells on the
194 right (Figure 2.D, Figure 2.E, Figure 2.F, top row). PAGA uses Leiden clustering internally, enabling
195 the following regions of the pseudotime map to be labelled objectively: 1) Islets with low
196 pseudotime values on the left of the map (PAGA-internal Leiden clusters 0 and 5 in Supplemental
197 Figure 2.A) were labelled "Normal" even if they originated from T1D donors. 2) Islets in the
198 middle of the map (PAGA-internal Leiden clusters 6, 2, and 8 in Supplemental Figure 2.A) were
199 elevated in HLA-ABC (MHC Class I) expression, CD8⁺T cells, and macrophage/DCs (Figure 2.D,
200 Figure 2.E, Figure 2.F, rows 2-4) and were labelled "Inflamed". 3) Islets with late pseudotime
201 values on the right of the map (PAGA-internal Leiden clusters 1,3,7, and 4 in Supplemental Figure
202 2.A) were devoid of β -cells and were labelled "Insulin-Depleted" (Figure 2.D, Figure 2.E, Figure
203 2.F, top row).

204 In addition, islets lacking β -cells occasionally contained CD8⁺T cells and were labelled "Insulin-
205 Depleted + Immune Islets" (Figure 2.D, Figure 2.E, Figure 2.F, rows 2-4). The presence of these
206 islets suggests that signals retaining CD8⁺T cells in islets linger after β -cells die. The distribution
207 of all cell types across pseudotime is reported in Supplemental Figure 2.B.

208 Islets from non-T1D controls and one of the AA+ donors (6314) were primarily in the Normal
209 group to the left of the map (Figure 2.C , Supplemental Figure 2.C). Islets from subjects who had
210 had T1D for of 5-6 years (cases 6195 and 6323) were primarily in the Insulin-Depleted group to
211 the right of the map (Figure 2.C , Supplemental Figure 2.C). All the remaining T1D donors and the
212 other AA+ donor were distributed broadly throughout the map (Figure 2.C , Supplemental Figure
213 2.C).

214 We quantified the fraction of each cell type in swaths at varying distances from the islet edge.
215 We found that for B Cells, CD4⁺T cells, CD8⁺T cells, macrophage/DCs, neutrophils, and plasma

216 cells, the fraction of the given cell type in the islet relative to outside the islets increased
217 (Supplemental Figure 2.D), demonstrating that the inflammation in islets was distinct from the
218 inflammation in the extra-islet tissue. Thus, immune cells were targeting islets specifically.

219 Together, these results illustrate a single, non-branching progression from Normal Islets to
220 Insulin-Depleted Islets via Inflamed Islets, consistent with previous pseudotime analyses
221 (Damond et al. 2019).

222 **IDO expression on islet vasculature is linked to T cell** 223 **infiltration**

224 We observed islets with vasculature staining positive for indoleamine 2, 3-dioxygenase 1 (IDO).
225 In the tumor microenvironment, IDO is commonly expressed by myeloid cells and suppresses
226 CD8⁺T cell activity through multiple mechanisms including the induction of FOXP3⁺ regulatory T
227 cells and the inhibition of CD8⁺T cell function (Munn and Mellor 2016). In islets, IDO co-stained
228 with CD31⁺ vasculature but not CD45⁺ immune cells adjacent to vasculature (Figure 2.G). IDO was
229 not expressed by endocrine or other cell types in islets or by vasculature or any cell type outside
230 islets (Supplemental Figure 2.E). We manually quantified vascular expression of IDO on islets
231 throughout pseudotime and found that all but two IDO⁺ islets were in the Inflamed group (Figure
232 2.H). Therefore, IDO expression by islet vasculature was tightly associated with insulinitis.

233 A potent inducer of IDO expression is Interferon- γ (IFN- γ), a cytokine highly expressed by
234 activated T cells and macrophages (Munn and Mellor 2016). Therefore, we hypothesized that IDO
235 expression was induced by infiltrating immune cells during insulinitis. We compared the frequency
236 of CD8⁺T cells and macrophage/DCs in islets from the Inflamed group with and without IDO⁺
237 vasculature and found that CD8⁺T cells were significantly more abundant in islets with IDO⁺
238 vasculature than islets without IDO⁺ vasculature (Figure 2.I). However, the abundance of $\gamma\delta$ -T
239 cells and CD4⁺T cells was less strongly associated with IDO⁺ vasculature and the abundance of
240 macrophage/DCs was not significantly associated with IDO⁺ vasculature (Supplemental Figure
241 2.F).

242 In summary, IDO expression by islet vasculature is positively associated with T cell infiltration and
243 may be an immunoregulatory checkpoint.

244 **Insulinitis has sub-states, defined by functional states of** 245 **CD8⁺T cells**

246 CD8⁺T cells are a major component of insulinitis (row 4 of Figure 2.E and Figure 2.F) and are capable
247 of directly and indirectly killing β -cells. A comprehensive description of the activation profiles of
248 CD8⁺T cells could provide insight into their roles in T1D pathogenesis. To obtain extremely high-
249 quality marker quantification, we trained a neural network on manually labelled images of single
250 T cells (Figure 3.A, Supplemental Figure 3.A). Using our neural network, we quantified the
251 expression of T cell markers on islet CD8⁺T cells (Figure 3.B).

252 PD-1, TOX, CD45RO, CD69, and CD44—markers of antigen experience—were the most commonly
253 expressed by islet-infiltrating CD8⁺T cells (Figure 3.B, Supplemental Figure 3.B). CD8⁺T cells
254 expressing CD45RA (which are either naïve or terminally differentiated effector memory cells
255 (TEMRA)) were detectable in islets, as previously reported (Damond et al. 2019) (Figure 3.B). In
256 addition, we observed a rare population of CD45RO⁺ CD8⁺T cells co-expressing Lag-3, Granzyme-
257 B, and ICOS (Figure 3.B bottom clade). Lastly, a rare population of CD57⁺ CD8⁺T cells was present
258 but these cells rarely co-expressed LAG-3, Granzyme-B, or ICOS (Figure 3.B top clade). These
259 populations resemble the two exhausted T cell populations identified in the peripheral blood of
260 T1D patients that were associated with responsiveness to alefacept (Diggins et al. 2021).
261 Therefore, the activation profiles of islet-infiltrating T cells are heterogeneous.

262 We reasoned that the islet microenvironment may dictate the activation state of CD8⁺T cells by
263 specifically recruiting T cells of a particular state and/or inducing changes after they enter the
264 islet. If so, islets would contain specific combinations of CD8⁺T cell states. To interrogate this, we
265 performed UMAP only on Inflamed islets, using the frequencies of CD8⁺T cells expressing each
266 functional marker. We identified four inflamed sub-clusters, I-IV, (Figure 3.C top). Here, the term
267 “sub-cluster” is used to highlight that these groups were all contained within the previously
268 defined “Inflamed” cluster and the roman numerals do not imply a temporal ordering. Inflamed-
269 I contained only CD8⁺T cells that did not express any of the functional markers analyzed (Figure
270 3.C bottom, top row). Inflamed-II was characterized by a high frequency of CD45RA⁺CD8⁺T cells
271 (Figure 3.C bottom, second row from top and Figure 3.D top row). Inflamed-III was characterized
272 by a low frequency of CD45RA⁺ cells and high frequency of CD45RO⁺ and PD-1⁺ cells (Figure 3.C
273 bottom, third row from top and Figure 3.D middle row). Inflamed-IV was characterized by an
274 enrichment of CD8⁺T cells expressing CD57, LAG-3, ICOS, Granzyme-B, PD-1 or CD45RO (Figure
275 3.C bottom, bottom row and Figure 3.D bottom row). In summary, the phenotypes of CD8⁺T cells
276 are coordinated across islets.

277 **Regulation of insulinitis sub-states by the islet** 278 **microenvironment**

279 To identify cellular or molecular factors that regulate the state of CD8⁺T cells in islets, we first
280 inspected the distribution of inflamed sub-clusters in each patient. Each donor possessed islets
281 that belonged to multiple inflamed islet sub-clusters (Figure 3.E). Therefore donor-level factors
282 such as genetics, the location within the pancreas (i.e. head, body, or tail), or time since T1D
283 onset, are not associated. Instead, these insulinitis sub-states are conserved among T1D patients.

284 Next, we asked if each T cell marker is enriched in CD8⁺T cells in islets compared to CD8⁺T cells in
285 the peri-islet and exocrine space. We computed the frequencies of each CD8⁺T cell state inside
286 islets of each inflamed sub-cluster and in separate swaths 0-25µm, 25-50µm and 50-100µm away
287 from the islets (Supplemental Figure 3.C). We found that for islets of Inflamed-II, -III, and -IV,
288 functional markers characterizing their CD8⁺T cells were expressed more frequently inside than
289 in the surrounding tissue areas. Although the different functional markers were all enriched on
290 islet-infiltrating T cells compared to T cells outside islets, the degree of this enrichment varied
291 across the markers measured. The markers of Inflamed-IV, LAG-3, ICOS, and Granzyme-B, were

292 highly enriched inside islets (~20% of islet-infiltrating CD8⁺T cells vs <5% of extra-islet CD8⁺T cells).
293 CD45RA and CD69 in Inflamed-II were slightly less enriched in islets (~28% of islet-infiltrating and
294 ~20% of extra-islet CD8⁺T cells). CD45RO and PD-1 in Inflamed-III islets were the most abundant
295 but had the least enrichment in islets (~45% of islet-infiltrating CD8⁺T cells vs ~35% of extra-islet
296 CD8⁺T cells) (Supplemental Figure 3.C). This demonstrated that the specific differences in the
297 compositions of CD8⁺T cell states in different islets were attributable to the islet
298 microenvironment and not the surrounding extra-islet spaces.

299 Although macrophage/DCs are abundant in islets from the Inflamed group (Figure 2.E, Figure 2.F)
300 and are capable of interacting with T cells through antigen presentation and cytokine secretion,
301 neither the expression of markers of macrophage/DC activity nor macrophage/DC abundance
302 was significantly associated with any of the inflamed sub-clusters (Supplemental Figure 3.D).
303 Similarly, no other cell-type nor the vascular expression of IDO was linked to CD8⁺T cell programs
304 in islets (Supplemental Figure 3.D). Accordingly, the four inflamed sub-clusters had identical
305 distributions throughout the original PAGA force-directed layout (Figure 3.F). Therefore, the
306 activation states of islet-infiltrating T cells are independent of the abundance of any of the other
307 cell types we could identify.

308 Lastly, we compared CD8⁺T cells in islets from the Insulin-Depleted + Immune group to CD8⁺T
309 cells in islets from the Inflamed group. Insulin-Depleted + Immune islets contained a higher
310 frequency of CD45RA⁺ CD8⁺T cells and a lower frequency of CD45RO⁺ CD8⁺T cells than Inflamed
311 islets (Figure 3.G). TOX was expressed by a higher frequency of CD8⁺T cells in Insulin-Depleted +
312 Immune islets than CD8⁺T cells in Inflamed islets (Figure 3.G). Importantly, CD45RA⁺ and TOX
313 were never co-expressed on the same CD8⁺T cell (Figure 3.B). These data indicate that the
314 activation state or persistence of these two populations in islets depends on insulin expression.

315 **Vasculature, nerves, and Granzyme-B⁺/CD3- cells** 316 **outside islets are associated with lobular patterning**

317 The destruction of islets in T1D is known to exhibit lobular patterning: that is, islets in the same
318 lobule are likely to be in the same stage of disease (Gepts 1965). The reason why islets within the
319 same lobule are synchronized is unknown. One explanation could be an islet-intrinsic mechanism
320 where the expression of programs sensitizing beta cells to immune-killing (i.e. stress) are
321 correlated across islets in the same lobule. Alternatively, it could be mediated by cells outside
322 islets if they facilitate extravasation into the lobule or trafficking from one afflicted islet to the
323 next.

324 To systematically investigate lobular patterning in T1D, we used a neural network to segment
325 lobules and assign each single cell and islet, to its lobule. We first quantified the degree of lobular
326 patterning within each donor using the intra-class correlation coefficient (ICC). The ICC ranges
327 from 0 to 1 where cases with values closer to 1 have islets whose states are more synchronized
328 within lobules (Figure 4.A). Islets of non-T1D cases and 6314, 6195, and 6323 did not have
329 appreciable variability in their pseudotimes, but in the remaining cases, the ICCs ranged from
330 0.17 to 0.74 (Figure 4.B). This highlights that the magnitude of lobular patterning ranges widely
331 across T1D cases with insulinitis.

332 We employed hierarchical linear modeling (HLM), a statistical framework designed to identify
333 relationships between levels of multi-level data. HLMs are standard in fields where multi-level
334 data are common such as Education, in which students are grouped into classrooms, which are
335 grouped into schools (Gelman et al. 2014) and have been applied in biomedical settings (Jerby-
336 Arnon and Regev 2022; Yi et al. 2019). We were interested in cell-types if their abundance in a
337 lobule correlated with the lobule's average islet pseudotime. Importantly, we omitted the islet
338 region itself from the calculation of a cell type's lobular abundance because we were interested
339 in identifying features in the extra-islet space that were associated with islet destruction. For
340 each cell type, we estimated the effect of its total abundance in a lobule (the number of cells
341 divided by the number of acinar cells to normalize for lobule area) on the pseudotimes of islets
342 in that lobule. We performed this analysis in two-level HLMs for each donor and a three-level
343 HLM considering all donors together (Figure 4.C).

344 We identified three cell types, vasculature, Granzyme-B⁺/CD3⁻ cells, that were significantly
345 associated with lobules across multiple T1D tissue donors. All three were more abundant in
346 lobules with islets late in pseudotime (Figure 4.C boxed rows, Figure 4.D). Samples from cases
347 6323 and 6195 which had very few insulin-containing islets had increased abundances of
348 vasculature, Granzyme-B/CD3⁻ cells, and nerves in their extra-islet spaces compared to non-T1D
349 controls (Supplemental Figure 1C), indicating these changes persist through the point when the
350 entire tissue is afflicted. In addition, vasculature, Granzyme-B⁺/CD3⁻ cells, and nerves were
351 increased in Inflamed islets compared to Normal islets indicating that they may serve a role in
352 islets in addition to their role in the extra-islet compartment (Supplemental Figure 4A). Note that
353 Supplemental Figure 4A differs from Supplemental Figure 1C because islets are broken up
354 according to pseudotime, not donor, and not all islets in T1D donors are undergoing insulinitis.

355 Counterintuitively, although CD8⁺T cells and macrophage/DCs were higher in the extra-islet
356 compartments of T1D cases vs non-T1D cases (Supplemental Figure 1C), they were not associated
357 with lobular patterning (they were not more abundant in the extra-islet space of lobules with
358 more advanced insulinitis) (Figure 4.C). These data raise the possibility that vasculature, Granzyme-
359 B/CD3⁻ cells, and nerves outside islets help predispose lobules to insulinitis or are affected by
360 extensive insulinitis.

361 **Immature tertiary lymphoid structures are enriched in** 362 **subjects with T1D**

363 We hypothesized that T cells' interactions with certain cell types in specific areas of the pancreas
364 may be important for their functionality. Therefore, we identified Cellular Neighborhoods (CNs)
365 (Schürch et al. 2020; Bhate et al. 2021), tissue regions that are homogeneous and have defined
366 cell-type compositions. To identify CNs, single cells were clustered according to the cell-type
367 composition of their twenty nearest spatial neighbors and automatically annotated with the
368 names of enriched cell types using (Figure 5.A, See Methods). This resulted in 75 CNs. Throughout
369 the manuscript, CNs are referred to with the nomenclature (Cell Type A|Cell Type B|...) to
370 indicate all the cell types that are enriched in them (See Methods).

371 Next, we identified CNs that were more abundant in T1D than non-T1D tissues (Figure 5.B). The
372 top three CNs (fold change of abundance in T1D relative to abundance in non-T1D) were (CD8⁺T
373 cells|B Cells), (Macrophage|Stromal Cells|B Cells), and (Vasculature|B Cells) (Figure 5.B, Figure
374 5.C). We asked whether these three CNs were commonly adjacent to each other as this could
375 indicate that they act as components of a larger structure (Bhate et al. 2021). Measuring the
376 frequency with which the three B cell CNs were adjacent to each other throughout the tissues
377 demonstrated that the (CD8⁺T cells|B Cells) CN is predominantly found adjacent to both the
378 other CNs but that (Macrophage|Stroma|B Cells) and (Vasculature|B Cells) are less commonly
379 adjacent to each other (Figure 5.D).

380 We next asked whether these CN assemblies corresponded to either peri-vascular cuffs (Agrawal
381 et al. 2013; Wekerle 2017) or tertiary lymphoid structures (TLSs) (Korpos et al. 2021; Rovituso et
382 al. 2016; Agrawal et al. 2013), as these are two B Cell-rich structures commonly present in
383 autoimmune conditions. Although the (CD8⁺T cells|B Cells) CN was adjacent to vessels (Figure
384 5.D, Figure 5.E), it was not in the fluid-filled perivascular space, as is the case with perivascular
385 cuffs (Figure 5.E). In our samples, the (CD8⁺T cells|B Cells) CN did not have segregated T cell and
386 B cell zones as seen in mature TLSs, consistent with (Korpos et al. 2021).

387 In summary, the (CD8⁺T cells|B Cells) CN is more abundant in T1D tissues from patients with
388 diabetes durations of 0-2 years compared to non-T1D tissues and T1D tissue from patients who
389 had T1D for more than 4 years.

390 **Immature tertiary lymphoid structures are in the extra-** 391 **islet pancreas, and are enriched in CD45RA⁺ /CD8⁺ T cells**

392 We next asked whether the (CD8⁺T cells|B Cells) CN had high endothelial venules (HEV),
393 specialized blood vessels that are commonly found in TLSs that enable naïve lymphocytes to
394 extravasate into peripheral tissues. We observed expression of peripheral lymph node addressin
395 (PNA⁺), an HEV marker, in the vessels associated with the (CD8⁺T cells|B Cells) CN (Figure 5.E left
396 image) but not in other vessels (data not shown). Although we could not assess the presence of
397 other TLS traits such as follicular dendritic cells, fibroblastic reticular cells, or follicular helper T
398 cells, the aggregation of B cells and presence of HEVs, but the lack of compartmentalized B and
399 T cell zones indicate that instances of the (CD8⁺T cells|B Cells) CN are immature TLSs.

400 Next, we asked if immature TLSs could support the entry of naïve CD8⁺T cells into the pancreas.
401 We observed CD8⁺T cells co-expressing CD45RA and CD62L (the ligand for PNA⁺) near PNA⁺
402 vasculature (Figure 5.E, middle and right image respectively). Thus, CD45RA⁺/CD8⁺T cells in the
403 pancreas can adhere to HEVs. Furthermore, CD45RA⁺ was enriched three-fold on CD8⁺T cells in
404 the (CD8⁺T cells|B Cells) CN relative to CD8⁺T cells in the tissue as a whole (Figure 5.F), providing
405 additional evidence that CD45RA⁺ T cells may enter the pancreas through HEVs.

406 We found immature TLS both adjacent (Figure 5.G.1) or not adjacent (Figure 5.G.2) to islets.
407 Quantifying the frequency of this adjacency revealed that fewer than half of the immature TLS
408 were adjacent to islets (Figure 5.H). We did not identify any differences in the cellular
409 composition of the immature TLS that were or were not adjacent to islets (Supplemental Figure
410 5). We reasoned that even if immature TLSs were far from islets, extravasating cells may migrate

411 to islets. Accordingly, islet-adjacent CD45RA⁺ CD8⁺T cells (that were not in islet-adjacent TLSs) co-
412 expressed CD62L, suggesting that they originated from the (CD8⁺T cells|B Cell) CN (Figure 5.I).
413 Consistent with this, in one notable tissue donor, regions of the pancreas with Insulin-Depleted
414 islets were enriched in the (CD8⁺T cells|B Cell) CN relative to regions of the pancreas with β -cell
415 containing islets (Figure 5.J). This spatial correlation between the (CD8⁺T cells|B Cells) CN and the
416 destruction of islets implicates immature TLS with islet pathology even if they are not adjacent
417 to islets (Figure 5.J).

418 Discussion

419 We have performed CODEX imaging and comprehensive computational analysis of whole
420 cadaveric pancreata from T1D subjects. Our data support several conclusions.

421 First, our results are consistent with the model previously proposed by Damond et al, who
422 proposed a single trajectory for insulinitis, characterized by an enrichment in HLA-ABC expression,
423 CD8⁺T cells, and macrophage/DCs (Damond et al. 2019).

424 Second, we are the first to report that IDO⁺ vasculature is present in inflamed islets but not in
425 normal islets or islets that have lost insulin-expression (Figure 2.G, Figure 2.H). Furthermore, islets
426 with IDO⁺ vasculature contained higher frequencies of CD8⁺T cells, but not macrophage/DCs
427 compared to inflamed islets that did not contain IDO⁺ vasculature, suggesting that IDO is induced
428 by a cytokine produced by infiltrating CD8⁺T cells such as IFN- γ (Figure 2.I). Given IDO's
429 established tolerogenic role, these data suggest that the loss of IDO on vasculature could be a
430 prerequisite for β -cell death. Leveraging this checkpoint to protect transplanted β -cells from
431 rejection has shown promise (Alexander et al. 2002) and could be combined with similar
432 approaches using programmed death-ligand 1 (Yoshihara et al. 2020; Castro-Gutierrez et al.
433 2021)

434 We did not observe IDO expression on β -cells, in contrast to Anquetil et al. that report this in
435 healthy patients (Anquetil et al. 2018). Our observations are consistent with data demonstrating
436 that IDO needs to be induced. First, it has been shown with western blot and RT-PCR that human
437 islets require cytokine stimulation to express IDO (Sarkar et al. 2007). Second, the human protein
438 atlas has tested multiple IDO antibodies and demonstrated that IDO is negative in human islets
439 via immunohistochemistry: (<https://www.proteinatlas.org>). In addition, the human protein
440 atlas's single-cell RNAseq atlas only report IDO transcripts in immune cells in healthy pancreas.

441 Third, we performed the first high-dimensional spatial phenotyping of CD8⁺T cells in T1D islets.
442 We found that most T cells were antigen experienced. A small population expressed CD45RA and
443 CD69, which could be naïve or TEMRA cells (Figure 3.B). Another population expressed Lag-3,
444 Granzyme-B, and ICOS. It is notable that only a small population of islets had Granzyme-B-
445 expressing T cells. This could indicate that alternative mechanisms are contributing to the
446 elimination of β -cells.

447 Fourth, the insulinitis trajectory is comprised of four sub-clusters, each characterized by the
448 activation profile of the islet-infiltrating CD8⁺T cells (Figure 3.C). Multiple of these inflamed sub-
449 clusters were present in all T1D donors, indicating that the sub-clusters are capable of inter-
450 converting (Figure 3.E). The factors that regulate the conversion of a given islet between sub-

451 clusters could correspond to immunoregulatory checkpoints that are critical to the progression
452 of T1D. Unfortunately, our search for such features failed to generate any candidates
453 (Supplemental Figure 3.D). By phenotyping T cells at different distances from the islet edge, we
454 were able to determine that the T cell activation profiles characterizing each sub-cluster were
455 only present in the islet, not in the surrounding tissue (Supplemental Figure 3.C). Unfortunately,
456 from our data, we cannot speculate whether the insulinitis sub-clusters arose due to differential
457 stimulation of T cells that had already entered islets, differential recruitment of pre-activated T
458 cells, or both.

459 Fifth, pancreatic lobules affected by insulinitis are characterized by distinct tissue markers. We
460 discovered that lobules enriched in β -cell-depleted islets were also enriched in nerves,
461 vasculature, and Granzyme-B⁺/CD3⁻ cells, suggesting these factors may make lobules permissive
462 to disease (Figure 4.C). The role of islet enervation in T1D has been studied but such work has
463 focused on nerves in the islet rather than on nerves in the exocrine tissue (Christoffersson, Ratliff,
464 and von Herrath 2020). The Granzyme-B⁺/CD3⁻ cells could be natural killer cells; if so, they are
465 most likely of the CD56dim subset as CD56 was not detected on these cells. It is noteworthy that
466 the cell types linked with direct islet invasion were distinct from those linked to lobule patterning
467 even though both sets of cell types were found across islet and extra-islet regions. Therefore, for
468 insulinitis to consume every islet, crosstalk may be required between the cell types in the islet and
469 extra-islet compartments. Conversely, inhibiting this interaction might contain pathology to
470 isolated lesions.

471 Finally, we identify immature TLS away from islets where CD45RA⁺ CD8⁺T cells aggregate. We
472 also observed an inflamed islet-subcluster characterized by an abundance of CD45RA⁺/CD8⁺ T
473 cells. It will be important to determine whether the CD45RA⁺ T cells localized around islets may
474 have originated from immature TLS. In mice, blocking immune egress from lymph nodes reduced
475 the size of TLSs and halted diabetes (Penaranda et al. 2010). Thus, therapeutic targeting of
476 immune cell trafficking to TLS could help mitigate autoimmunity in human T1D.

477 Together, these data illuminate relationships between insulinitis, the local islet microenvironment
478 and inflammation at distal sites.

479 A major limitation for the study is the cohort size. Cases with documented insulinitis are very rare,
480 significantly limiting the feasibility of curating large cohorts (Campbell-Thompson et al. 2016).
481 Due to this limitation, factors such as the donors' histories of drug use, durations of stay in the
482 intensive care unit, and BMIs could not be balanced or statistically adjusted for but should be
483 considered when relevant and are associated with exocrine inflammation but not the prevalence
484 of insulinitis (Bruggeman et al. 2021). In addition, only one of the AA⁺ cases, Case 6267, had
485 detectable insulinitis (Figure 2.C). The other case, 6314 tested positive for only one autoantibody,
486 GADA⁺, and therefore had a significantly lower probability of progressing to overt T1D (Ziegler et
487 al. 2013).

488 Another limitation is our limited perspective on myeloid cell populations. Although antibodies in
489 our panel detect numerous myeloid markers, we failed to identify any heterogeneity in myeloid
490 populations during insulinitis. This was likely due in part to the difficulty of segmenting myeloid
491 cells and quantifying marker expression due to their morphology. Spatial transcriptomics could

492 be used in future studies to better define the myeloid populations and inform additions to future
493 CODEX panels.

494 Lastly, our samples are 2-dimensional sections which could affect some of the adjacency
495 relations.

496 In conclusion, using a data-driven approach, we mapped conserved sub-states of insulinitis and
497 integrated the spatial pathology of islet and extra-islet regions into a single model of T1D
498 pathogenesis. The tools and computational pipelines developed here will enable further
499 investigation of immune pathology at the tissue scale that may lead to development of therapies
500 for T1D.
501

502 **Methods**

503 **Human tissues**

504 Cadaveric pancreatic FFPE tissue sections were obtained through the nPOD program, sponsored
505 by the Juvenile Diabetes Research Fund. Case numbers cited herein are assigned by nPOD and
506 comparable across nPOD-supported projects. 17 cases in the nPOD biorepository had been
507 previously documented to contain insulinitis. For each of these 17 cases, we examined the triple
508 stained immunohistochemistry images (CD3, Insulin, and Glucagon) using nPOD's online
509 pathology database to select blocks in which insulinitis was present. To ensure that the tissue
510 regions still contained insulinitis (and had not been sectioned extensively after their images were
511 uploaded to the nPOD pathology database), we re-sectioned and visualized CD3, Insulin, and
512 Glucagon. The use of cadaveric human tissue samples is approved by Stanford University's
513 Institutional Review Board.
514

515 **CODEX data collection**

516 *CODEX Antibody Generation and Validation.* Oligonucleotides were conjugated to purified,
517 carrier-free, commercially available antibodies as previously described (Schürch et al. 2020;
518 Kennedy-Darling et al. 2021). For validation experiments, human tonsils and non-diabetic
519 pancreata were co-embedded in FFPE blocks so both tissues could be stained and imaged
520 simultaneously. Each antibody in the CODEX panel was validated by co-staining with previously
521 established antibodies targeting positive and negative control cell types. Once validated, the
522 concentration and imaging exposure time of each antibody were optimized. The tissue staining
523 patterning was compared to the online database, The Human Protein Atlas, and the published
524 literature. The specificity, sensitivity, and reproducibility of CODEX staining has been previously
525 validated (Schürch et al. 2020; Kennedy-Darling et al. 2021; Black et al. 2021; Phillips, Schürch, et
526 al. 2021; Phillips, Matusiak, et al. 2021)
527

528 *CODEX Staining.* Staining and imaging was conducted as previously described (Schürch et al.
529 2020; Kennedy-Darling et al. 2021; Phillips, Schürch, et al. 2021; Black et al. 2021). Briefly, FFPE
530 tissues were deparaffinized and rehydrated. Heat-induced epitope retrieval (HIER) antigen
531 retrieval was conducted in Tris/EDTA buffer at pH9 (Dako) at 97°C for 10 minutes. Tissues were

532 blocked for 1 hour with rat and mouse Ig, salmon-sperm DNA, and a mixture of the non-
533 fluorescent DNA oligo sequences used as CODEX barcodes. Tissues were stained with the
534 antibody cocktail in a sealed humidity chamber overnight at 4°C with shaking. The next day,
535 tissues were washed, fixed with 1.6% paraformaldehyde, 100% methanol, and BS3 (Thermo
536 Fisher Scientific), and mounted to a custom-made acrylic plate attached to the microscope.

537
538 *CODEX Imaging.* Imaging was conducted using the Keyence BZ-X710 fluorescence microscope
539 with a CFI Plan Apo λ 20x/0.75 objective (Nikon). “High resolution” mode was selected in Keyence
540 Navigator software, resulting in a final resolution of .37744 $\mu\text{m}/\text{pixel}$. The exposure times are
541 listed in Supplemental Table 3. Regions for imaging were selected by rendering HLA-ABC,
542 Proinsulin, and CD8 and selecting large regions (averaging 55mm²). The full antibody panel and
543 cycle-ordering is detailed in (Supplemental Tables 3 and 4). Biotinylated hyaluronan-binding
544 protein was rendered by adding streptavidin-PE at 1:500 concentration to the 96 well plate
545 containing fluorescent oligos in the last cycle and running the CODEX program normally. DRAQ5
546 was added to the last cycle because we found it stained nuclei more evenly than HOECHST which
547 slightly improved segmentation. Each tissue took between 3 and 7 days to image depending on
548 the tissue area.

549
550 *Characterization of Tertiary Lymphoid Structures.* A serial section from case 6228 was imaged in
551 a separate CODEX experiment using an antibody panel tailored for characterizing tertiary
552 lymphoid structures, as described in Supplemental Table 3. These data were acquired and
553 analyzed identically to the main dataset.

554
555 *Image Pre-processing.* Drift compensation, deconvolution, z-plane selection was performed using
556 the CODEX Toolkit uploader (github.com/nolanlab/CODEX, Goltsev et al. 2018). Cell
557 segmentation using the DRAQ5 nuclear channel and lateral bleed compensation was performed
558 with CellSeg (Lee et al. 2022).

559

560 Cell Type Clustering and Annotation

561 Marker expression was z-normalized within each donor and subsequently clustered in two steps.
562 First, cells were projected into 2 dimensions using the markers indicated in Supplemental Table
563 2 and Parametric Uniform Manifold Approximation and Projection (pUMAP)(Sainburg, McInnes,
564 and Gentner 2021) was applied on a downsampled dataset. The fit model was used to transform
565 the remaining cells. Cell types were gated using Leiden clustering and manual merging. The
566 cluster containing immune cells was sub-clustered using the markers detailed in Supplemental
567 Table 2. Acinar cells contaminating the Immune cluster were gated out and merged with the
568 Acinar cluster from the previous step. The Endocrine class was sub-clustered into α -, β -, and δ -
569 Cells using Glucagon, Proinsulin, and Somatostatin respectively. Clusters were annotated
570 according the heatmap marker expression, and overlaying annotations onto raw images
571 (Supplemental Figure 1.A) using custom scripts in Fiji.

572

573 Islet Segmentation and Pseudotime

574 *Preprocessing.* Windows consisting of the twenty nearest spatial neighbors surrounding each
575 single cell were clustered according to their cell-type composition using Mini Batch K Means with
576 $k=200$. For this analysis, α -, β -, and δ -Cells were combined into one ‘Endocrine’ cell type. One
577 cluster was highly enriched in Endocrine cells and accurately defined the islet area. Individual
578 islets were identified using the connected components algorithm and filtering out islets that had
579 fewer than ten total cells.

580
581 *PAGA Analysis.* For each islet, the number of each cell type inside the islet and between the islet
582 edge and $20\mu\text{m}$ beyond were extracted. To adjust for variation due to the islet size, the cell type
583 counts were divided by the number of endocrine cells inside the islet. Data were then log-
584 transformed. The PAGA embedding was computed using the default parameters except for the
585 following: The neighborhood search was performed using cosine distance and 15 nearest
586 neighbors; Leiden clustering used a resolution of 1. For computing the pseudotime values (used
587 in the colormap in Figure 2B, the x-axis in Figure 2F, and Figure 4), the path through the inflamed
588 islet was isolated by temporarily omitting 25 islets positioned in the middle of the map between
589 Normal and Insulin-Depleted islets. Only 9 of these were from T1D or AA+ donors.

590

591 Quantification and Validation of Functional Marker Gating

592 *Annotation of Ground-Truth Dataset.* 4000 CD8⁺T cells were labelled for fifteen markers by an
593 immunologist familiar with the staining patterns of each marker using VGG Image annotator
594 (Abhishek Dutta and Andrew Zisserman 2019).

595

596 *Automated Thresholding.* For each functional marker of interest, the lateral-bleed-compensated
597 mean fluorescence (Lee et al. 2022) of cell types known to not express the marker in question
598 were used to calculate a background distribution. Marker-positive cells were defined as those
599 whose expression was greater than the 99th percentile of the background distribution.

600

601 *Gating with Neural Network:* $22\mu\text{m} \times 22\mu\text{m}$ cropped images of each single cell were used as
602 training data. The marker that the image corresponded to was not included as an input in the
603 neural network and one classifier was trained for all markers. Cells were split into training,
604 validation, and test splits (60/15/25 respectively). ResNet50 architecture and initial weights were
605 imported from the Keras library pre trained on ImageNet. Image augmentation consisted of
606 random flips, rotations, zooms, contrast, and translation (+/- ten pixels only). All weights were
607 unfrozen, and the model was trained for 100 epochs (see accompanying source code for training
608 details).

609

610 Sub-clustering of Inflamed Islets with Cell-Type specific Functional 611 Markers

612 For each Inflamed Islet ($n=351$), the frequency of each marker expressed by CD8⁺T cells was
613 computed. Single cells inside the islet and within $20\mu\text{m}$ from the islet’s edge were combined
614 before the frequency was measured. The subsequent matrix underwent z-normalization

615 followed by UMAP gating using Bokeh. Insulin-Depleted + Immune Islets were defined as islets
616 without β -cells with greater than two CD8⁺T cells and greater than seven macrophage/DCs. These
617 thresholds correspond to the 95th percentiles of CD8⁺T cells and macrophage/DCs in Normal
618 islets.
619

620 Identification of Cellular Neighborhoods

621 Previously, CNs (Schürch et al. 2020) were identified by, for each single cell, defining its ‘window’
622 as the 20 spatial nearest neighbors. Cells were clustered according to the number of each cell
623 type in their windows using Mini Batch K-Means. The output clusters corresponded to CNs. To
624 ensure our method was sensitive to rare neighborhoods, we adapted this algorithm by
625 intentionally over-clustering, using $k=200$ in the K- Means step rather than using a k ranging from
626 10-20 as used elsewhere (Bhate et al. 2021; Phillips, Matusiak, et al. 2021; Shekarian et al. 2022).
627 Next, to determine which cell types were characteristic of each cluster, we identified, for each
628 cluster, the set of cell-types that were present in more than 80% of the windows allocated to that
629 cluster. We named the clusters according to this set of cell-types and merged all clusters with the
630 same name, resulting in seventy-five CNs. Acinar cells and epithelial cells were used in the kNN
631 graph and in the clustering but were not considered when merging clusters. Note that this
632 method does not differentiate neighborhoods that have the same combination of cell types but
633 different stoichiometries.

634 Lobule Segmentation

635 A training dataset was generated by manually tracing the edges of lobules in ImageJ using the
636 ROI function. The ROI were then floodfilled in Python and used as masks for training. For each
637 tile, the blank cycle was selected to distinguish tissue from background coverslip. A U-Net
638 model was trained for 10 epochs (see attached source code for training details). After stitching
639 together all masks, the resulting images required slight refinement where lobules were not
640 completely separated, and this was done manually in ImageJ. The connected components in the
641 stitched image defined the lobule instances. Cells were assigned to a lobule by indexing the
642 lobule mask with their X and Y coordinates. Cells in the inter-lobular space were assigned to
643 one “edge” lobule. This resulted in 464 lobules.
644

645 Formulation of Hierarchical Linear Models

646 For each lobule, the number of each cell type in the extra-islet space was divided by the
647 number of acinar cells in the extra-islet space. For all HLMs, the *lme4* package for R was used
648 (Bates et al. 2015) and statistical significance was computed using the *lmerTest* package for R
649 (Kuznetsova, Brockhoff, and Christensen 2017). Lobular cell-type abundance was z-normalized
650 within each donor and the pseudotime was z-normalized across the entire dataset prior to
651 fitting.
652

653 The ICC was computed using the model: $pseudotime_{islet} \sim 1 | lobuleID$ with the *performance*
654 package in R. A value of 0 indicates that the variation in pseudotimes of islets within the same
655 lobule is equal to the variation across all islets in the donor and a value of 1 indicates that the

656 variation in pseudotimes of islets within the same lobule is much smaller than that of all islets in
657 the donor.

658
659 For each cell type, a two-level, random intercept HLM within each donor was constructed with
660 the following formulation (in R formula syntax): $pseudotime_{islet} \sim celltype_{lobule} + (1|lobuleID)$ and
661 a three-level random intercept, random slope HLM including islets from all donors was
662 formulated: $pseudotime_{islet} \sim celltype_{lobule} + (1 + celltype_{lobule} | donorID) + (1|lobuleID)$. Here,
663 $pseudotime_{islet}$ equals the pseudotime of each islet, $celltype_{lobule}$ equals the number of the given
664 cell type in a particular lobule divided by the number of acinar cells in that lobule, z-normalized
665 within each donor, and $lobuleID$ and $donorID$ are categorical variables specifying the lobule and
666 donor that the given islet belongs to.

667

668 Neighborhood Adjacency

669 The adjacency between neighborhoods was computed as in (Bhate et al. 2021). The only
670 modification was that neighborhood instances were identified using connected components of
671 the k-NN graph with k=5 rather than from the thresholded images.

672 Data Availability


673 Processed single cell dataframes are accessible at:

674
675 <https://www.dropbox.com/sh/8sqef3iwjb6f4wp/AAAQzFgDOgMBiWh9Jqcb81U8a?dl=0>.

676
677 The raw and stitched, processed data is hosted by the BioImage Archive
678 (<https://www.ebi.ac.uk/bioimage-archive/>) with the accession number
679 S-BIAD859.

680 Code Availability

681 All primary code is attached with the supplementary information and will be posted on the Nolan
682 Lab's github upon acceptance. The code is completely open source. The code is not intended as
683 a software tool and so no small example data set is applicable.



684

685 **Figure 1 Profiling T1D pancreata with CODEX high-parameter imaging reveals alterations**
 686 **in islet and extra-islet regions.**

687 Figure 1.A Left: Schematic of the workflow for selection of nPOD cases. Blues, greens, and reds
 688 indicate non-T1D, AA+, or T1D status, respectively. Center: Schematic for acquisition and
 689 processing of CODEX highly multiplexed imaging dataset. Right: Schematic of islet and extra-islet
 690 pancreatic regions.

691 Figure 1.B UMAP and Leiden clustering of major cell types. Colors match those in the heatmap
 692 shown to the right. Heatmap of mean z-normalized marker expression in each cell-type cluster.
 693 Only a subset of the markers used for the UMAP are included in the heatmap to facilitate

694 visualization. A full description of the markers used for the clustering stages is available in
695 Supplemental Table 2.


696 Figure 1.C UMAP of the immune population identified in Figure 1B further clustered using
697 additional immune markers as described in Supplemental Table 2. Colors match those in heatmap
698 shown in the heatmap to the right. The heatmap is generated in an identical manner as the
699 heatmap in Figure 1B.

700 Figure 1.D Frequency of β -Cells per donor determined by dividing the number of β -cells by the
701 total number of β -cells, α -cells, and δ -Cells. Blues, greens, and reds indicate non-T1D, AA+, or
702 T1D status, respectively. Significance was determined using the t-test (* $p < 0.05$, ** $p < 0.01$, ***
703 $p < 0.001$)

704 Figure 1.E Principal component analysis of the islet compartment. The number of cells of each
705 cell type (omitting α -, β -, and δ -cells) were divided by the number of endocrine cells to adjust for
706 different islet areas. Blues, greens, and reds indicate non-T1D, AA+, or T1D status, respectively.

707 Figure 1.F Principal component analysis of the extra-islet compartment. The number of cells of
708 each cell type (omitting α -, β -, and δ -cells) were divided by the number of acinar cells to adjust
709 for different areas imaged. Blues, greens, and reds indicate non-T1D, AA+, or T1D status,
710 respectively.

711



712
713

714 **Figure 2 Pseudotemporal reconstruction of insulinitis identifies IDO on islet vasculature.**

715 Figure 2.A Schematic of islet segmentation and quantification of islet cellular composition.

716 Figure 2.B PAGA-force directed layout of islets colored by pseudotime. The start point of
717 pseudotime was calculated as the centroid of the non-T1D islets. Representative islets from
718 different stages of pseudotime are indicated with black points and their raw images are depicted
719 in Figure 2.D. Normal, Inflamed, and Insulin-Depleted were identified by examining the cell
720 composition of the clusters obtained internally by the PAGA algorithm (Supplemental Figure 2.A).

721 Figure 2.C Islet distribution across pseudotime for each donor. The titles indicate nPOD case IDs
722 as in Supplemental Table 1. The frequency of islets from each donor in each stage of islet
723 pseudotime is reported in Supplemental Figure 2.C.

724 Figure 2.D Images of Proinsulin, HLA-ABC, CD163, and CD8 staining in islets representative of
725 different points along pseudotime as indicated in B. Scale bars (lower left of each column)
726 indicate 100μm.


727 Figure 2.E Quantification of selected features across pseudotime overlaid onto the PAGA force-
728 directed layout. For β -cells, macrophage/DCs, and CD8⁺T cells, the values correspond to log(#
729 cells/# endocrine cells). For HLA-ABC, the mean HLA-ABC expression for each cell in the islet was
730 computed and log transformed.

731 Figure 2.F Quantification of selected features across pseudotime. For β -cells, macrophage/DCs,
732 and CD8⁺T cells, the values correspond to log(# cells/# endocrine cells). For HLA-ABC, the mean
733 HLA-ABC expression for each cell in the islet was computed and log transformed. Color legend:
734 Normal islets: pink; Inflamed islets: brown; Insulin-Depleted islets: purple. Black points
735 demarcate LOWESS regression.

736 Figure 2.G Representative image of an islet from the Inflamed group stained with IDO and, from
737 left to right, Synaptophysin, CD31, and CD45. Arrows indicate IDO⁺/CD31⁺ vasculature. Right
738 shows that IDO⁺ cells are negative for CD45 and therefore, are not myeloid cells associated with
739 vasculature. Scale bar (bottom left image) indicates 50 μ m.

740 Figure 2.H Distribution of IDO expression on islet vasculature across pseudotime.

741 Figure 2.I Association of IDO⁺ islet vasculature with islet CD8⁺T cell density. The y-axis corresponds
742 to the number of CD8⁺T cells per endocrine cell per islet. CD8⁺T cell counts were normalized to
743 adjust for islet size. The x-axis indicates whether islets contain IDO⁺ vasculature. Each color
744 corresponds to a donor. All donors with detectable IDO⁺ Islet vasculature are displayed which
745 consisted of 6480, 6267, 6520, 6228, and 6362. Colors are same as in Figure 2.C. IDO⁺ vasculature
746 was manually quantified. For combined donors, significance was determined with a mixed-effect
747 linear model, $p = 1.5 \times 10^{-12}$ (Satterthwaites's method lmerTest R package). The complete
748 breakdown per donor is reported in Supplemental Figure 2.F.



749

750

751 **Figure 3 Insulinitis has sub-states, characterized by CD8⁺T cell functionality**

752 Figure 3.A Schematic of marker-quantification with a ResNet50 neural network. Raw images are
753 input, and the neural network outputs a number between 0 and 1 indicative of the level of
754 confidence that the cell expresses that marker with 1 indicating the highest confidence.

755 Figure 3.B Heatmap of all 2,855 Inflamed Islet CD8⁺T cells, hierarchically clustered according to
756 marker expression predicted by the neural network.


757 Figure 3.C Top) UMAP of Inflamed Islets based on frequencies of markers on CD8⁺T cells in islets.
758 Bottom) Mean frequencies of each marker on CD8⁺T cells in islets of each inflamed sub-cluster.

759 Figure 3.D Representative images of islets from each subcluster with associated immune markers.
760 Scale bars indicate 50 μ m.

761 Figure 3.E Frequencies of islets from each subcluster per donor in AA+ and T1D samples. Color
762 indicates subcluster as in panel C.

763 Figure 3.F Distribution of the islets of Inflamed-I through -IV on the PAGA force-directed layout
764 shown in Figure 2.B

765 Figure 3.G Differences in marker expression frequencies between CD8⁺T cells in islets from the
766 Inflamed group and from the Insulin-Depleted + Immune group. T cells from all islets of the
767 specified groups were pooled within each donor to compute the frequencies of marker
768 expression. Significance was determined using the Wilcoxon signed-rank test (* $p < 0.05$, **
769 $p < 0.01$, *** $p < 0.001$) and was not corrected for multiple hypothesis testing.



770


771 **Figure 4 Vasculature, nerves, and Granzyme-B⁺/CD3- cells in the extra-islet pancreas are**
 772 **associated with the lobular patterning of islet pathogenesis**

773 Figure 4.A A schematic of the method for quantifying lobular patterning of insulinitis. Lobules were
 774 segmented and colored accordingly. The islets are colored according to their composition of b-
 775 cells and a-cells. Top: A region from case 6228 with a strong lobular grouping effect and an ICC
 776 closer to 1. Bottom: A region from case 6267 with a weak lobular grouping effect and an ICC
 777 closer to 0.

778 Figure 4.B Lobular patterning of insulinitis within each donor. Each point represents an islet. The x-
 779 axis represents the islet pseudotime. The y-axis is ordinal, representing the rank of each lobule
 780 according to the mean pseudotime of its islets. Violin plots per lobule are overlaid. Abbreviations:
 781 ICC: Intraclass correlation coefficient.

782 Figure 4.C Cell types associated with lobular patterning. Top: Schematic of the hierarchical linear
 783 model. Cells in islets were omitted when computing the lobular abundance of each cell-type.
 784 Bottom: Coefficients of two-level models trained on each donor separately (columns labeled by
 785 donor) and a three-level model (right column). Color corresponds to the coefficient and features
 786 with $p > 0.05$ are white. Significance was determined using Satterthwaites's method in the
 787 lmerTest R package. No adjustment for multiple hypothesis testing was applied.

788 Figure 4.D Visualization of vasculature (top), Granzyme-B/CD3- cells (middle), and nerves
 789 (bottom) in two lobules. The left lobule represents lobules with islets earlier in pseudotime and
 790 a lower abundance of the given cell type in the lobule. The right lobule represents lobules with
 791 islets late in pseudotime and a greater abundance of the given cell type in the lobule.



792

793 **Figure 5 Immature tertiary lymphoid structures far from islets are potential staging areas for**
 794 **islet-destined CD8⁺T cells**

795 Figure 5.A Schematic of algorithm for identifying CNs. Red point indicates index cell for the CN.
 796 Orange points indicate the nearest neighbors of the index cell. Windows are collected for each
 797 cell in the dataset (indicated by orange arrows).

798 Figure 5.B Cell-type compositions of the top CNs organized in decreasing order of the fold
 799 increase in abundance in T1D vs. non-T1D samples. Each column in the heatmap indicates the
 800 mean density of that cell type in the 20 nearest spatial neighbors of cells assigned to the CN
 801 designated for that row. CN abundance was calculated as the number of cells assigned to the
 802 given CN divided by the number of acinar cells. Abbreviations: Vasc.: vasculature; Mac.:

803 macrophage/DCs; Lym.: lymphatics. Neu.: neutrophils; CD8 T: CD8⁺T cells; CD4 T: CD4⁺T cells.
804 Endocrine cell types were merged during CN annotation and are labeled “Islet”.

805 Figure 5.C Mean abundances of the CD8⁺T cell and B cell CNs per donor. Abundance was
806 calculated as the number of cells assigned to the given CN divided by the number of acinar cells.
807 Significance was determined using the Mann-Whitney U test (* p<0.05, ** p<0.01, *** p<0.001).
808 No adjustment for multiple hypothesis testing was applied.

809 Figure 5.D Top: Adjacency frequencies of (CD8⁺T cells| B Cell CN) with (Macrophage|Stroma|B
810 Cells) and (Vasculature| B Cells) CNs. The adjacency frequency was calculated as the number of
811 instances of the source CN adjacent to the destination CN divided by the total number of
812 instances of the source CN. Bottom Left: Raw image of a representative assembly of the three
813 CNs (CD8⁺T cells| B Cell CN), (Macrophage|Stroma|B Cells), and (Vasculature| B Cells) displaying
814 CD8 and CD20 staining. Bottom Right: The same assembly as to the left colored by CN. Scale bar
815 indicates 50µm).

816 Figure 5.E Representative images of co-localization of PNA⁺ endothelium and CD45RA⁺ CD62L⁺
817 CD8⁺T cells located in the (CD8⁺T cells| B Cells) CN. Scale bar indicates 50µm.

818 Figure 5.F Frequency of CD45RA expression on CD8⁺T cells located in (CD8⁺T cell | B cell) CN
819 relative to CD8⁺T cells throughout the tissue. Significance was determined with a Wilcoxon
820 signed-rank test (* p<0.05, ** p<0.01, *** p<0.001).

821 Figure 5.G Representative images of (CD8⁺T cells|B Cells) instances adjacent to islets (G.1) and
822 not adjacent to islets (G.2). Scale bars indicate 200µm.

823 Figure 5.H Quantification of the adjacency frequencies between the (CD8⁺T cells| B Cells) CN and
824 CNs rich in endocrine cells (i.e “Islet CNs”). Mean, std: mean and standard deviation adjacency
825 frequency across T1D donors. Abbreviations: Vasc.: vasculature; Mac.: macrophage.

826 Figure 5.I Representative images of islet-adjacent CD45RA⁺ CD62L⁺ CD8⁺T cells. Scale bar
827 indicates 50 µm.

828 Figure 5.J Image showing the spatial distribution of the (CD8⁺T cells|B cells) CN instances relative
829 to islets and the enrichment of (CD8⁺T cells|B cells) CN instances in areas of the pancreas with
830 islets lacking β-Cells.

831 References

- 832 Abhishek Dutta and Andrew Zisserman. 2019. "The VIA Annotation Software for Images, Audio
833 and Video." In . MM '19. Nice, France: ACM. <https://doi.org/10.1145/3343031.3350535>.
- 834 Agrawal, Smriti M., Jacqueline Williamson, Ritu Sharma, Hania Kebir, Kamala Patel, Alexandre
835 Prat, and V. Wee Yong. 2013. "Extracellular Matrix Metalloproteinase Inducer Shows
836 Active Perivascular Cuffs in Multiple Sclerosis." *Brain* 136 (6): 1760–77.
837 <https://doi.org/10.1093/brain/awt093>.
- 838 Alexander, Angela M., Megan Crawford, Suzanne Bertera, William A. Rudert, Osamu Takikawa,
839 Paul D. Robbins, and Massimo Trucco. 2002. "Indoleamine 2,3-Dioxygenase Expression
840 in Transplanted NOD Islets Prolongs Graft Survival After Adoptive Transfer of
841 Diabetogenic Splenocytes." *Diabetes* 51 (2): 356–65.
842 <https://doi.org/10.2337/diabetes.51.2.356>.
- 843 Anquetil, Florence, Giada Mondanelli, Nathaly Gonzalez, Teresa Rodriguez Calvo, Jose Zapardiel
844 Gonzalo, Lars Krogvold, Knut Dahl-Jørgensen, et al. 2018. "Loss of IDO1 Expression From
845 Human Pancreatic β -Cells Precedes Their Destruction During the Development of Type 1
846 Diabetes." *Diabetes* 67 (9): 1858–66. <https://doi.org/10.2337/db17-1281>.
- 847 Arif, Sefina, Pia Leete, Vy Nguyen, Katherine Marks, Nurhanani Mohamed Nor, Megan
848 Estorninho, Deborah Kronenberg-Versteeg, et al. 2014. "Blood and Islet Phenotypes
849 Indicate Immunological Heterogeneity in Type 1 Diabetes." *Diabetes* 63 (11): 3835–45.
850 <https://doi.org/10.2337/db14-0365>.
- 851 Atkinson, Mark A., and Raghavendra G. Mirmira. 2023. "The Pathogenic 'Symphony' in Type 1
852 Diabetes: A Disorder of the Immune System, β Cells, and Exocrine Pancreas." *Cell*
853 *Metabolism* 35 (9): 1500–1518. <https://doi.org/10.1016/j.cmet.2023.06.018>.
- 854 Bates, Douglas, Martin Mächler, Ben Bolker, and Steve Walker. 2015. "Fitting Linear Mixed-
855 Effects Models Using Lme4." *Journal of Statistical Software* 67 (October):1–48.
856 <https://doi.org/10.18637/jss.v067.i01>.
- 857 Bender, Christine, Teresa Rodriguez-Calvo, Natalie Amirian, Ken T. Coppieters, and Matthias G.
858 von Herrath. 2020. "The Healthy Exocrine Pancreas Contains Preproinsulin-Specific CD8
859 T Cells That Attack Islets in Type 1 Diabetes." *Science Advances* 6 (42): eabc5586.
860 <https://doi.org/10.1126/sciadv.abc5586>.
- 861 Bhate, Salil S., Graham L. Barlow, Christian M. Schürch, and Garry P. Nolan. 2021. "Tissue
862 Schematics Map the Specialization of Immune Tissue Motifs and Their Appropriation by
863 Tumors." *Cell Systems*, October. <https://doi.org/10.1016/j.cels.2021.09.012>.
- 864 Black, Sarah, Darci Phillips, John W. Hickey, Julia Kennedy-Darling, Vishal G. Venkatarraaman,
865 Nikolay Samusik, Yury Goltsev, Christian M. Schürch, and Garry P. Nolan. 2021. "CODEX
866 Multiplexed Tissue Imaging with DNA-Conjugated Antibodies." *Nature Protocols* 16 (8):
867 3802–35. <https://doi.org/10.1038/s41596-021-00556-8>.
- 868 Bluestone, Jeffrey A., Jane H. Buckner, and Kevan C. Herold. 2021. "Immunotherapy: Building a
869 Bridge to a Cure for Type 1 Diabetes." *Science* 373 (6554): 510–16.
870 <https://doi.org/10.1126/science.abh1654>.
- 871 Bruggeman, Brittany S., Martha Campbell-Thompson, Stephanie L. Filipp, Matthew J. Gurka,
872 Mark A. Atkinson, Desmond A. Schatz, and Laura M. Jacobsen. 2021. "Substance Use

- 873 Affects Type 1 Diabetes Pancreas Pathology: Implications for Future Studies." *Frontiers*
874 *in Endocrinology* 12. <https://www.frontiersin.org/articles/10.3389/fendo.2021.778912>.
- 875 Campbell-Thompson, Martha, Ann Fu, John S. Kaddis, Clive Wasserfall, Desmond A. Schatz,
876 Alberto Pugliese, and Mark A. Atkinson. 2016. "Insulinitis and β -Cell Mass in the Natural
877 History of Type 1 Diabetes." *Diabetes* 65 (3): 719–31. [https://doi.org/10.2337/db15-](https://doi.org/10.2337/db15-0779)
878 0779.
- 879 Campbell-Thompson, Martha, Teresa Rodriguez-Calvo, and Manuela Battaglia. 2015.
880 "Abnormalities of the Exocrine Pancreas in Type 1 Diabetes." *Current Diabetes Reports*
881 15 (10): 79. <https://doi.org/10.1007/s11892-015-0653-y>.
- 882 Campbell-Thompson, Martha, Clive Wasserfall, John Kaddis, Anastasia Albanese-O'Neill,
883 Teodora Staeva, Concepcion Nierras, Jayne Moraski, et al. 2012. "Network for
884 Pancreatic Organ Donors with Diabetes (nPOD): Developing a Tissue Biobank for Type 1
885 Diabetes." *Diabetes/Metabolism Research and Reviews* 28 (7): 608–17.
886 <https://doi.org/10.1002/dmrr.2316>.
- 887 Castro-Gutierrez, Roberto, Aimon Alkanani, Clayton E. Mathews, Aaron Michels, and Holger A.
888 Russ. 2021. "Protecting Stem Cell Derived Pancreatic Beta-Like Cells From Diabetogenic
889 T Cell Recognition." *Frontiers in Endocrinology* 12.
890 <https://www.frontiersin.org/articles/10.3389/fendo.2021.707881>.
- 891 Christoffersson, Gustaf, Sowbarnika S. Ratliff, and Matthias G. von Herrath. 2020. "Interference
892 with Pancreatic Sympathetic Signaling Halts the Onset of Diabetes in Mice." *Science*
893 *Advances* 6 (35): eabb2878. <https://doi.org/10.1126/sciadv.abb2878>.
- 894 Dalmas, Elise, Frank M. Lehmann, Erez Dror, Stephan Wueest, Constanze Thienel, Marcela
895 Borsigova, Marc Stawiski, et al. 2017. "Interleukin-33-Activated Islet-Resident Innate
896 Lymphoid Cells Promote Insulin Secretion through Myeloid Cell Retinoic Acid
897 Production." *Immunity* 47 (5): 928-942.e7.
898 <https://doi.org/10.1016/j.immuni.2017.10.015>.
- 899 Damond, Nicolas, Stefanie Engler, Vito R. T. Zanotelli, Denis Schapiro, Clive H. Wasserfall, Irina
900 Kusmartseva, Harry S. Nick, et al. 2019. "A Map of Human Type 1 Diabetes Progression
901 by Imaging Mass Cytometry." *Cell Metabolism* 29 (3): 755-768.e5.
902 <https://doi.org/10.1016/j.cmet.2018.11.014>.
- 903 Diggins, Kirsten E., Elisavet Serti, Virginia Muir, Mario Rosasco, TingTing Lu, Elisa Balmas, Gerald
904 Nepom, S. Alice Long, and Peter S. Linsley. 2021. "Exhausted-like CD8⁺ T Cell Phenotypes
905 Linked to C-Peptide Preservation in Alefacept-Treated T1D Subjects." *JCI Insight* 6 (3).
906 <https://doi.org/10.1172/jci.insight.142680>.
- 907 Fasolino, Maria, Gregory W. Schwartz, Abhijeet R. Patil, Aanchal Mongia, Maria L. Golson, Yue J.
908 Wang, Ashleigh Morgan, et al. 2022. "Single-Cell Multi-Omics Analysis of Human
909 Pancreatic Islets Reveals Novel Cellular States in Type 1 Diabetes." *Nature Metabolism* 4
910 (2): 284–99. <https://doi.org/10.1038/s42255-022-00531-x>.
- 911 Gelman, Andrew, John B Carlin, Hal S Stern, David B Dunson, Aki Vehtari, and Donald B Rubin.
912 n.d. "Bayesian Data Analysis Third Edition (with Errors Fixed as of 15 February 2021),"
913 677.
- 914 Gepts, Willy. 1965. "Pathologic Anatomy of the Pancreas in Juvenile Diabetes Mellitus."
915 *Diabetes* 14 (10): 619–33. <https://doi.org/10.2337/diab.14.10.619>.

- 916 Goltsev, Yury, Nikolay Samusik, Julia Kennedy-Darling, Salil Bhate, Matthew Hale, Gustavo
917 Vazquez, Sarah Black, and Garry P. Nolan. 2018. "Deep Profiling of Mouse Splenic
918 Architecture with CODEX Multiplexed Imaging." *Cell* 174 (4): 968-981.e15.
919 <https://doi.org/10.1016/j.cell.2018.07.010>.
- 920 Gregory, Gabriel A., Thomas I. G. Robinson, Sarah E. Linklater, Fei Wang, Stephen Colagiuri,
921 Carine de Beaufort, Kim C. Donaghue, et al. 2022. "Global Incidence, Prevalence, and
922 Mortality of Type 1 Diabetes in 2021 with Projection to 2040: A Modelling Study." *The
923 Lancet Diabetes & Endocrinology* 10 (10): 741–60. [https://doi.org/10.1016/S2213-
924 8587\(22\)00218-2](https://doi.org/10.1016/S2213-8587(22)00218-2).
- 925 Herold, Kevan C., Brian N. Bundy, S. Alice Long, Jeffrey A. Bluestone, Linda A. DiMeglio,
926 Matthew J. Dufort, Stephen E. Gitelman, et al. 2019. "An Anti-CD3 Antibody,
927 Teplizumab, in Relatives at Risk for Type 1 Diabetes." *New England Journal of Medicine*
928 381 (7): 603–13. <https://doi.org/10.1056/NEJMoa1902226>.
- 929 Herold, Kevan C., Stephen E. Gitelman, Mario R. Ehlers, Peter A. Gottlieb, Carla J. Greenbaum,
930 William Hagopian, Karen D. Boyle, et al. 2013. "Teplizumab (Anti-CD3 mAb) Treatment
931 Preserves C-Peptide Responses in Patients With New-Onset Type 1 Diabetes in a
932 Randomized Controlled Trial: Metabolic and Immunologic Features at Baseline Identify a
933 Subgroup of Responders." *Diabetes* 62 (11): 3766–74. [https://doi.org/10.2337/db13-
934 0345](https://doi.org/10.2337/db13-0345).
- 935 Hickey, John W., Yuqi Tan, Garry P. Nolan, and Yury Goltsev. 2021. "Strategies for Accurate Cell
936 Type Identification in CODEX Multiplexed Imaging Data." *Frontiers in Immunology* 12.
937 <https://www.frontiersin.org/article/10.3389/fimmu.2021.727626>.
- 938 Hirsch, James S. 2023. "FDA Approves Teplizumab: A Milestone in Type 1 Diabetes." *The Lancet
939 Diabetes & Endocrinology* 11 (1): 18. [https://doi.org/10.1016/S2213-8587\(22\)00351-5](https://doi.org/10.1016/S2213-8587(22)00351-5).
- 940 In't Veld, Peter. 2011. "Insulinitis in Human Type 1 Diabetes: The Quest for an Elusive Lesion."
941 *Islets* 3 (4): 131–38. <https://doi.org/10.4161/isl.3.4.15728>.
- 942 In't Veld, Peter. 2014. "Insulinitis in Human Type 1 Diabetes: A Comparison between Patients and
943 Animal Models." *Seminars in Immunopathology* 36 (5): 569–79.
944 <https://doi.org/10.1007/s00281-014-0438-4>.
- 945 Jerby-Arnon, Livnat, and Aviv Regev. 2022. "DIALOGUE Maps Multicellular Programs in Tissue
946 from Single-Cell or Spatial Transcriptomics Data." *Nature Biotechnology* 40 (10): 1467–
947 77. <https://doi.org/10.1038/s41587-022-01288-0>.
- 948 Kennedy-Darling, Julia, Salil S. Bhate, John W. Hickey, Sarah Black, Graham L. Barlow, Gustavo
949 Vazquez, Vishal G. Venkataraman, et al. 2021. "Highly Multiplexed Tissue Imaging
950 Using Repeated Oligonucleotide Exchange Reaction." *European Journal of Immunology*
951 51 (5): 1262–77. <https://doi.org/10.1002/eji.202048891>.
- 952 Korpos, Éva, Nadir Kadri, Reinhild Kappelhoff, Jeannine Wegner, Christopher M. Overall,
953 Ekkehard Weber, Dan Holmberg, Susanna Cardell, and Lydia Sorokin. 2013. "The Peri-
954 Islet Basement Membrane, a Barrier to Infiltrating Leukocytes in Type 1 Diabetes in
955 Mouse and Human." *Diabetes* 62 (2): 531–42. <https://doi.org/10.2337/db12-0432>.
- 956 Korpos, Éva, Nadir Kadri, Sophie Loismann, Clais R. Findeisen, Frank Arfuso, George W. Burke,
957 Sarah J. Richardson, et al. 2021. "Identification and Characterisation of Tertiary
958 Lymphoid Organs in Human Type 1 Diabetes." *Diabetologia* 64 (7): 1626–41.
959 <https://doi.org/10.1007/s00125-021-05453-z>.

- 960 Krogvold, Lars, Bjørn Edwin, Trond Buanes, Johnny Ludvigsson, Olle Korsgren, Heikki Hyöty, Gun
961 Frisk, Kristian F. Hanssen, and Knut Dahl-Jørgensen. 2014. "Pancreatic Biopsy by Minimal
962 Tail Resection in Live Adult Patients at the Onset of Type 1 Diabetes: Experiences from
963 the DiViD Study." *Diabetologia* 57 (4): 841–43. [https://doi.org/10.1007/s00125-013-](https://doi.org/10.1007/s00125-013-3155-y)
964 3155-y.
- 965 Kuznetsova, Alexandra, Per B. Brockhoff, and Rune H. B. Christensen. 2017. "lmerTest Package:
966 Tests in Linear Mixed Effects Models." *Journal of Statistical Software* 82 (December):1–
967 26. <https://doi.org/10.18637/jss.v082.i13>.
- 968 Lee, Michael Y., Jacob S. Bedia, Salil S. Bhate, Graham L. Barlow, Darci Phillips, Wendy J. Fantl,
969 Garry P. Nolan, and Christian M. Schürch. 2022. "CellSeg: A Robust, Pre-Trained Nucleus
970 Segmentation and Pixel Quantification Software for Highly Multiplexed Fluorescence
971 Images." *BMC Bioinformatics* 23 (1): 46. <https://doi.org/10.1186/s12859-022-04570-9>.
- 972 Leete, Pia, Abby Willcox, Lars Krogvold, Knut Dahl-Jørgensen, Alan K. Foulis, Sarah J. Richardson,
973 and Noel G. Morgan. 2016. "Differential Insulinitic Profiles Determine the Extent of β -Cell
974 Destruction and the Age at Onset of Type 1 Diabetes." *Diabetes* 65 (5): 1362–69.
975 <https://doi.org/10.2337/db15-1615>.
- 976 Martino, Luisa, Matilde Masini, Marco Bugliani, Lorella Marselli, Mara Suleiman, Ugo Boggi,
977 Tatiane C. Nogueira, et al. 2015. "Mast Cells Infiltrate Pancreatic Islets in Human Type 1
978 Diabetes." *Diabetologia* 58 (11): 2554–62. <https://doi.org/10.1007/s00125-015-3734-1>.
- 979 Munn, David H., and Andrew L. Mellor. 2016. "IDO in the Tumor Microenvironment:
980 Inflammation, Counter-Regulation, and Tolerance." *Trends in Immunology* 37 (3): 193–
981 207. <https://doi.org/10.1016/j.it.2016.01.002>.
- 982 Orban, Tihamer, Brian Bundy, Dorothy J. Becker, Linda A. DiMeglio, Stephen E. Gitelman, Robin
983 Goland, Peter A. Gottlieb, et al. 2011. "Co-Stimulation Modulation with Abatacept in
984 Patients with Recent-Onset Type 1 Diabetes: A Randomised, Double-Blind, Placebo-
985 Controlled Trial." *Lancet (London, England)* 378 (9789): 412–19.
986 [https://doi.org/10.1016/S0140-6736\(11\)60886-6](https://doi.org/10.1016/S0140-6736(11)60886-6).
- 987 ———. 2014. "Costimulation Modulation With Abatacept in Patients With Recent-Onset Type 1
988 Diabetes: Follow-up 1 Year After Cessation of Treatment." *Diabetes Care* 37 (4): 1069–
989 75. <https://doi.org/10.2337/dc13-0604>.
- 990 Penaranda, Cristina, Qizhi Tang, Nancy H. Ruddle, and Jeffrey A. Bluestone. 2010. "Prevention
991 of Diabetes by FTY720-Mediated Stabilization of Peri-Islet Tertiary Lymphoid Organs."
992 *Diabetes* 59 (6): 1461–68. <https://doi.org/10.2337/db09-1129>.
- 993 Perdigoto, Ana Luisa, Paula Preston-Hurlburt, Pamela Clark, S. Alice Long, Peter S. Linsley,
994 Kristina M. Harris, Steven E. Gitelman, et al. 2019. "Treatment of Type 1 Diabetes with
995 Teplizumab: Clinical and Immunological Follow-up after 7 Years from Diagnosis."
996 *Diabetologia* 62 (4): 655–64. <https://doi.org/10.1007/s00125-018-4786-9>.
- 997 Pescovitz, Mark D., Carla J. Greenbaum, Heidi Krause-Steinrauf, Dorothy J. Becker, Stephen E.
998 Gitelman, Robin Goland, Peter A. Gottlieb, et al. 2009. "Rituximab, B-Lymphocyte
999 Depletion, and Preservation of Beta-Cell Function." *New England Journal of Medicine*
1000 361 (22): 2143–52. <https://doi.org/10.1056/NEJMoa0904452>.
- 1001 Phillips, Darci, Magdalena Matusiak, Belén Rivero Gutierrez, Salil S. Bhate, Graham L. Barlow,
1002 Sizun Jiang, Janos Demeter, et al. 2021. "Immune Cell Topography Predicts Response to

- 1003 PD-1 Blockade in Cutaneous T Cell Lymphoma.” *Nature Communications* 12 (1): 6726.
1004 <https://doi.org/10.1038/s41467-021-26974-6>.
- 1005 Phillips, Darci, Christian M. Schürch, Michael S. Khodadoust, Youn H. Kim, Garry P. Nolan, and
1006 Sizun Jiang. 2021. “Highly Multiplexed Phenotyping of Immunoregulatory Proteins in the
1007 Tumor Microenvironment by CODEX Tissue Imaging.” *Frontiers in Immunology*
1008 12:687673. <https://doi.org/10.3389/fimmu.2021.687673>.
- 1009 Pugliese, Alberto, Mingder Yang, Irina Kusmarteva, Tiffany Heiple, Francesco Vendrame, Clive
1010 Wasserfall, Patrick Rowe, et al. 2014. “The Juvenile Diabetes Research Foundation
1011 Network for Pancreatic Organ Donors with Diabetes (nPOD) Program: Goals,
1012 Operational Model and Emerging Findings.” *Pediatric Diabetes* 15 (1): 1–9.
1013 <https://doi.org/10.1111/pedi.12097>.
- 1014 Richardson, Sarah J., and Alberto Pugliese. 2022. “100 YEARS OF INSULIN: Pancreas Pathology in
1015 Type 1 Diabetes: An Evolving Story.” *Journal of Endocrinology* 252 (2): R41–57.
1016 <https://doi.org/10.1530/JOE-21-0358>.
- 1017 Rodriguez-Calvo, Teresa, Olov Ekwall, Natalie Amirian, Jose Zapardiel-Gonzalo, and Matthias G.
1018 von Herrath. 2014. “Increased Immune Cell Infiltration of the Exocrine Pancreas: A
1019 Possible Contribution to the Pathogenesis of Type 1 Diabetes.” *Diabetes* 63 (11): 3880–
1020 90. <https://doi.org/10.2337/db14-0549>.
- 1021 Rovituso, Damiano M., Laura Scheffler, Marie Wunsch, Christoph Kleinschnitz, Sebastian Dörck,
1022 Jochen Ulzheimer, Antonios Bayas, Lawrence Steinman, Süleyman Ergün, and Stefanie
1023 Kuerten. 2016. “CEACAM1 Mediates B Cell Aggregation in Central Nervous System
1024 Autoimmunity.” *Scientific Reports* 6 (July):29847. <https://doi.org/10.1038/srep29847>.
- 1025 Saelens, Wouter, Robrecht Cannoodt, Helena Todorov, and Yvan Saeys. 2019. “A Comparison of
1026 Single-Cell Trajectory Inference Methods.” *Nature Biotechnology* 37 (5): 547–54.
1027 <https://doi.org/10.1038/s41587-019-0071-9>.
- 1028 Sainburg, Tim, Leland McInnes, and Timothy Q. Gentner. 2021. “Parametric UMAP Embeddings
1029 for Representation and Semi-Supervised Learning.” arXiv.
1030 <https://doi.org/10.48550/arXiv.2009.12981>.
- 1031 Sarkar, Suparna A., Randall Wong, Seija I. Hackl, Ong Moua, Ronald G. Gill, Alexander Wiseman,
1032 Howard W. Davidson, and John C. Hutton. 2007. “Induction of Indoleamine 2,3-
1033 Dioxygenase by Interferon-Gamma in Human Islets.” *Diabetes* 56 (1): 72–79.
1034 <https://doi.org/10.2337/db06-0617>.
- 1035 Savinov, Alexei Y., F. Susan Wong, Austin C. Stonebraker, and Alexander V. Chervonsky. 2003.
1036 “Presentation of Antigen by Endothelial Cells and Chemoattraction Are Required for
1037 Homing of Insulin-Specific CD8+ T Cells.” *The Journal of Experimental Medicine* 197 (5):
1038 643–56. <https://doi.org/10.1084/jem.20021378>.
- 1039 Schürch, Christian M., Salil S. Bhate, Graham L. Barlow, Darci J. Phillips, Luca Noti, Inti Zlobec,
1040 Pauline Chu, et al. 2020. “Coordinated Cellular Neighborhoods Orchestrate Antitumoral
1041 Immunity at the Colorectal Cancer Invasive Front.” *Cell*, August.
1042 <https://doi.org/10.1016/j.cell.2020.07.005>.
- 1043 Shekarian, Tala, Carl P. Zinner, Ewelina M. Bartoszek, Wandrille Duchemin, Anna T.
1044 Wachnowicz, Sabrina Hogan, Manina M. Etter, et al. 2022. “Immunotherapy of
1045 Glioblastoma Explants Induces Interferon- γ Responses and Spatial Immune Cell

- 1046 Rearrangements in Tumor Center, but Not Periphery.” bioRxiv.
1047 <https://doi.org/10.1101/2022.01.19.474897>.
- 1048 Wang, Yue J., Daniel Traum, Jonathan Schug, Long Gao, Chengyang Liu, Mark A. Atkinson, Alvin
1049 C. Powers, et al. 2019. “Multiplexed In Situ Imaging Mass Cytometry Analysis of the
1050 Human Endocrine Pancreas and Immune System in Type 1 Diabetes.” *Cell Metabolism*
1051 29 (3): 769–783.e4. <https://doi.org/10.1016/j.cmet.2019.01.003>.
- 1052 Wekerle, Hartmut. 2017. “B Cells in Multiple Sclerosis.” *Autoimmunity* 50 (1): 57–60.
1053 <https://doi.org/10.1080/08916934.2017.1281914>.
- 1054 Wilcox, Nicholas S, Jinxiu Rui, Matthias Hebrok, and Kevan C Herold. 2016. “Life and Death of β
1055 Cells in Type 1 Diabetes: A Comprehensive Review.” *Journal of Autoimmunity* 71
1056 (July):51–58. <https://doi.org/10.1016/j.jaut.2016.02.001>.
- 1057 Wolf, F. Alexander, Fiona K. Hamey, Mireya Plass, Jordi Solana, Joakim S. Dahlin, Berthold
1058 Göttingens, Nikolaus Rajewsky, Lukas Simon, and Fabian J. Theis. 2019. “PAGA: Graph
1059 Abstraction Reconciles Clustering with Trajectory Inference through a Topology
1060 Preserving Map of Single Cells.” *Genome Biology* 20 (1): 59.
1061 <https://doi.org/10.1186/s13059-019-1663-x>.
- 1062 Yi, Nengjun, Zaixiang Tang, Xinyan Zhang, and Boyi Guo. 2019. “BhGLM: Bayesian Hierarchical
1063 GLMs and Survival Models, with Applications to Genomics and Epidemiology.”
1064 *Bioinformatics* 35 (8): 1419–21. <https://doi.org/10.1093/bioinformatics/bty803>.
- 1065 Yoshihara, Eiji, Carolyn O’Connor, Emanuel Gasser, Zong Wei, Tae Gyu Oh, Tiffany W. Tseng,
1066 Dan Wang, et al. 2020. “Immune-Evasive Human Islet-like Organoids Ameliorate
1067 Diabetes.” *Nature* 586 (7830): 606–11. <https://doi.org/10.1038/s41586-020-2631-z>.
- 1068 Ziegler, Anette G., Marian Rewers, Olli Simell, Tuula Simell, Johanna Lempainen, Andrea Steck,
1069 Christiane Winkler, et al. 2013. “Seroconversion to Multiple Islet Autoantibodies and
1070 Risk of Progression to Diabetes in Children.” *JAMA* 309 (23): 2473–79.
1071 <https://doi.org/10.1001/jama.2013.6285>.
- 1072
1073

1074 **Acknowledgements**

1075 This research was performed with the support of the Network for Pancreatic Organ donors with
1076 Diabetes (nPOD; RRID:SCR_014641), a collaborative type 1 diabetes research project supported
1077 by JDRF (nPOD: 5-SRA-2018-557-Q-R) and The Leona M. & Harry B. Helmsley Charitable Trust
1078 (Grant#2018PG-T1D053, G-2108-04793). The content and views expressed are the responsibility
1079 of the authors and do not necessarily reflect the official view of nPOD. Organ Procurement
1080 Organizations (OPO) partnering with nPOD to provide research resources are listed
1081 at <http://www.jdrfnpod.org/for-partners/npod-partners/>. Research reported in this publication
1082 was supported by the National Cancer Institute and National Institute of Allergy and Infectious
1083 Diseases of the National Institutes of Health under Award Numbers K99CA246061,
1084 5U54CA209971-05, 5U2CCA233195-02, 1U2CCA233238-01, 5U2CCA233195-02, 5U01AI101984-09. The
1085 content is solely the responsibility of the authors and does not necessarily represent the official
1086 views of the National Institutes of Health. C.M.S. was supported by the Swiss National Science
1087 Foundation (P300PB_171189, P400PM_183915). We like to thank Yury Goltsev, Pauline Chu,
1088 Sarah Black, Gustavo Vazquez, Aviv Hargil (Stanford University), and Irina Kusmartseva (nPOD)
1089 for excellent assistance. We like to thank Dr. Xavier Rovira-Clavé (Stanford University) for critical
1090 comments on the manuscript.

1091 **Author information**

1092 G.L.B curated data, wrote software, and analyzed data. D.P. and C.M.S contributed significantly
1093 to validating the antibody panel and assisted with analysis. S.D., S.S.B, A.Y., H.A.M., G.K.K., N.N.,
1094 S.R., and J.M. assisted with analysis. G.L.B., J.A.B., G.P.N., and P.L.B., conceptualized the study
1095 and wrote the manuscript. All authors have read and approved the final version of the
1096 manuscript.

1097 **Ethics declarations**

1098 P.L.B.: Founder, Halo Biosciences.

1099 N.N.: Founder, Halo Biosciences.

1100 PLB, NN and GK have filed intellectual property around 4-MU. PLB, NN and GK hold a financial
1101 interest in Halo Biosciences, a company that is developing 4-MU for various indications.

1102 G.P.N. has received research grants from Vaxart and Celgene during the course of this work and
1103 has equity in and is a scientific advisory board member of Akoya Biosciences. Akoya Biosciences
1104 makes reagents and instruments that are dependent on licenses from Stanford University.
1105 Stanford University has been granted US patent 9909167, which covers some aspects of the
1106 technology described in this paper.


1107 J.A.B.: Board of director for Gilead and CEO and President of Sonoma Biotherapeutics; scientific
1108 advisory boards of Arcus Biotherapeutics and Cimeio Therapeutics; consultant for Rheos
1109 Medicines, Provention Bio; stockholder in Rheos Medicines, Vir Therapeutics, Arcus
1110 Biotherapeutics, Solid Biosciences, Celsius Therapeutics; Gilead Sciences, Provention Bio,
1111 Sonoma Biotherapeutics.

1112 C.M.S.: Scientific advisory board of, stock options in, research funding from Enable Medicine, Inc.


1 Supplemental Information

2


A



B



C




3

4 Supplemental Figure 1 Related to Figure 1.

5 Supplemental Figure 1.A Validation of cell annotations. Dots were overlaid on images of
 6 characteristic markers colored by cell type. In each panel, the cell types and their corresponding
 7 colors are indicated and the markers and their corresponding colors are specified.

8 Supplemental Figure 1.B The total number of endocrine cells measured in each donor.

9 Supplemental Figure 1.C Changes in cellular abundance in Islet (top) and extra-islet (bottom)
 10 regions. The Y-axis corresponds to the number of the given cell type / number of endocrine
 11 cells in the top row and the number of a given cell type / number of acinar cells in the bottom
 12 row in each donor. These frequencies were then z-normalized across donors.
 13



15 **Supplemental Figure 2** **Related to Figure 2.**

16 Supplemental Figure 2.A Leiden clustering computed by PAGA algorithm internally. Clusters 0
17 and 5 were assigned to the 'Healthy' group. Clusters 6, 2, and 8 were assigned to the "Inflamed"
18 group. Clusters 1,3,7, and 4 were assigned to the "Insulin-Depleted" group.

19 Supplemental Figure 2.B The density of other cell types per islet across pseudotime. Same as
20 Figure 2.E.

21 Supplemental Figure 2.C The number of islets of each stage of pseudotime and the total
22 number of cells per case.


23 Supplemental Figure 2.D For each cell type, the frequency of that cell type inside islets, within
24 100µm of the islet edge, and 100µm-150µm from the islet edge was quantified.

25 Supplemental Figure 2.E Frequency of IDO on vasculature at different distances from islets.
26 Dashed line indicates the frequency in and around islets where IDO⁺ was detected in islet
27 vasculature (n=84) as in Figure 2.H. Solid line indicates the frequency in and around Inflamed
28 Islets in which IDO was absent in islet vasculature (n=267). Error bars indicate 95% confidence
29 intervals obtained by iteratively calculating the marker frequency in re-sampled islets with
30 replacement (n=200)

31 Supplemental Figure 2.F CD8⁺T cell, Macrophage, γ/δ T cell, and CD4⁺T cell abundance in IDO⁺
32 and IDO⁻ islets. Same as Figure 2.I. Asterisks in figure indicate significance within each donor
33 (Satterthwaites's method lmerTest R package).

34

35



36

37 **Supplemental Figure 3 Related to Figure 3**

38 Supplemental Figure 3.A Validation of neural network for detecting expression of T cell
 39 markers. Recall and Precision for the neural network. The table was computed using cells in the
 40 “Test” dataset.

41 Supplemental Figure 3.B Frequency of functional markers on CD8⁺T cells inside islets. Colors
 42 correspond to donor. Only AA+ and T1D donors are cells displayed.


43 Supplemental Figure 3.C Frequency of functional markers on CD8⁺T cells at different distances
 44 from islets. Error bars indicate 95% confidence intervals obtained by iteratively calculating the
 45 marker frequency in re-sampled islets with replacement (n=200).

46 Supplemental Figure 3.D Association of islet features with Inflamed-I through -IV. For each
 47 feature (columns), a mixed-level model adjusting for donor was fit in a one-vs-all design and the
 48 p-value was determined using Satterthwaites’s method in lmerTest R package. Values in the
 49 heatmap were corrected for multiple hypotheses using the Benjamini, Hochberg method.

50

51

52




53

54 **Supplemental Figure 4 Related to Figure 4**

55 Supplemental Figure 4 Changes in cell types identified by HLM in insulinitis. Each point represents
 56 and islet. Islets are grouped according to the pseudotime analysis from Figure 2. The y-axis
 57 corresponds to the log-transformed values for the number of the given cell type / number of
 58 endocrine cells. Significance was determined using the t-test (* p<0.05, ** p<0.01, *** p<0.001).
 59 No adjustment for multiple hypothesis testing was applied.

60



61

62 **Supplemental Figure 5 Related to Figure 5**

63 Supplemental Figure 5 Association of the cell composition of the CD8+T cells | B Cells CN with
 64 islet proximity. For each feature (columns), a mixed-level model adjusting for donor was fit
 65 against instances that were or were not < 20μm from an islet and the p-value was determined
 66 using Satterthwaites’s method in lmerTest R package. Values in the heatmap were corrected for
 67 multiple hypotheses using the Benjamini, Hochberg method.

68

CaseID	Donor Type	Age (years)	Diabetes Duration (years)	Cause of Death	Sex	Ethnicity	BMI	nPOD RRID
6267	Autoab positive	23	NA	Anoxia	Female	Caucasian	16.59	SAMN15879321
6314	Autoab positive	21	NA	Head Trauma	Male	Caucasian	23.8	SAMN15879368
6520	T1D	21.61	0	Cerebrovascular/	Male	Caucasian	29.3	SAMN18053203
6362	T1D	24.9	0	Head Trauma	Male	Caucasian	28.5	SAMN15879415
6228	T1D	13	0	Anoxia	Male	Caucasian	17.4	SAMN15879284
6209	T1D	5	0.25	Cerebral edema secondary to DKA	Female	Caucasian	15.9	SAMN15879265
6371	T1D	12.5	2	Cerebral edema	Female	Caucasian	16.6	SAMN15879424
6480	T1D	17.18	2	DKA	Male	Caucasian	27.1	SAMN15879533
6195	T1D	19.3	5	Head Trauma	Male	Caucasian	23.7	SAMN15879251
6323	T1D	22	6	Anoxia	Female	Caucasian	24.7	SAMN15879377
6389	No diabetes	18.6	NA	Head Trauma	Male	Caucasian	20.9	SAMN15879442
6179	No diabetes	20	NA	Head Trauma	Female	Caucasian	20.7	SAMN15879235
6386	No diabetes	14	NA	Head Trauma	Male	Caucasian	23.9	SAMN15879439

69

70

Supplemental Table 1: nPOD Case Information

Both	"All" UMAP	"Immune" UMAP	Endocrine Cells	Un-used ****
Channel 2 Blank*	alphaSMA	VISTA	Glucagon	CD44
Channel 3 Blank*	Synaptophysin	TCR g/d	Insulin	CD45RA
Channel 4 Blank*	Podoplanin	MPO	Proinsulin	CD45RO
S100A6	PD-L1 ***	HLA-DR	Somatostatin	ColIV
Hoechst**	NaKATPase	FOXP3		HABP
Granzyme B	MUC-1	CD8		HLA-ABC
Galectin-3	Draq 5	CD69		ICOS
CD68	Cytokeratin	CD4		IDO
CD57	Chromogranin A	CD206		Ki67
CD56	CD31	CD16		Lag3
CD45		CD11c		OX40
CD3		BCL-2		PD-1
CD20				TOX
CD163				
CD15				
CD138				

71
72 **Supplemental Table 2: Markers used for cell-type identification.** Channels in the "Both" column
73 were used for clustering all cells and specifying immune cells. Channels in the "All" column were
74 only used for clustering all cells and the UMAP in Figure 1.B. Channels in "Immune" columns were
75 only used for sub-clustering immune cells and the UMAP in Figure 1.C. Channels in "Endocrine"
76 column were used for sub-clustering endocrine populations. Channels in "Un-used" column were
77 not included in the clustering or UMAP step because they were either too weak to aid clustering
78 or were expressed on multiple cell-populations and confounded cell-type identification.

79

80 **Main Panel**

	AntiBody	A488	ExposuresTime	AntiBody	A555	ExposuresTime	AntiBody	A647	ExposuresTime
Cycle 1	ColIV	33	333	NaKATPase	36	100	HLA-ABC	53	100
Cycle 2	blank	blank	1000	blank	blank	1000	blank	blank	1000
Cycle 3	Ki67	6	100	BCL-2	46	500	TOX	28	150
Cycle 4	Chromogranin A	43	16	empty		1	FOXP3	61	1000
Cycle 5	Proinsulin	63	40	Galectin-3	60	166	empty		1
Cycle 6	Glucagon	24	50	Podoplanin	32	500	Insulin	30	200
Cycle 7	CD8	8	125	CD31	68	100	Lag3	42	500
Cycle 8	CD15	14	40	CD45RA	7	333	PD-1	23	500
Cycle 9	MPO	51	117	CD69	52	500	PD-L1	11	500
Cycle 10	S100A6	70	500	empty		1	CD3	77	500
Cycle 11	MUC-1	21	33	CD20	48	167	CD4	20	500
Cycle 12	Cytokeratin	67	100	CD16	15	250	CD11c	49	500
Cycle 13	alphaSma	69	50	CD163	45	100	empty		1
Cycle 14	CD57	57	300	Somatostatin	2	100	CD56	29	333
Cycle 15	CD44	44	250	CD206	55	400	CD45RO	3	500
Cycle 16	TCR g/d	72	1000	CD45	56	250	ICOS	41	500
Cycle 17	empty		1	Synaptophysin	26	250	Granzyme B	81	100
Cycle 18	empty		1	HLA-DR	65	250	OX40	66	400
Cycle 19	empty		1	VISTA	79	500	CD138	76	200
Cycle 20	empty		1	IDO	59	2500	CD68	5	100
Cycle 21	empty		1	HABP	1/100 StrPE	13	Draq 5		115

81

82

83

84

85 **Tertiary Lymphoid Structure Panel**

	AntiBody	A488	ExposuresTime	AntiBody	A555	ExposuresTime	AntiBody	A647	Dilution
Cycle 1	Chromogranin A	43	16	CD20	48	167	CD3	77	500
Cycle 2	Proinsulin	63	40	CD31	68	100	CD45RO	3	500
Cycle 3	CD8	8	125	CD45RA	7	333	CD4	20	500
Cycle 4	Ki67	6	100	Podoplanin	32	500	CD138	76	200
Cycle 5	Glucagon	24	50	CD62L	38	250	PnAD	71	333
Cycle 6	alphaSma	69	50				CollIV	33	333

86
87
88
89

Supplemental Table 3: CODEX Experiment Details

Marker	Clone	Vendor	Identifier
CollIV	poly	Abcam	ab6586
Ki67	B56	BD	556003
Chromogranin A	.K2H10 + PHE5 + CGA/41	Novus	NBP2-34674
Proinsulin	3A1	Thermo	MA122710
Glucagon	K7bB10	Abcam	ab10988
CD8	C8/144B	Santa Cruz	sc-53212
CD15	MMA	BD	559045
MPO	poly	R&D	AF3667
S100A6	7D11	Novus	NB100-1765
MUC-1	955	NSJ Bioreagents	V23725AF
Cytokeratin	C11	Biologend	628602
alphaSma	polyclonal	abcam	ab5694
CD57	HCD57	Biologend	359602
CD44	IM-7	Biologend	103002
TCR g/d	H-41	Santa Cruz	sc-100289
NaKATPase	EP1845Y	Abcam	ab167390
BCL-2	124	Cell Marque	custom
Galectin-3	A3A12	Thermo	MA1940
Podoplanin	NC-08	Biologend	916606
CD31	C31.3 + C31.7 + C31.10	Novus Bio	NBP2-47785
CD45RA	HI100	Biologend	555486
CD69	poly (AF2359)	Novus	AF2359
CD20	rIGEL/773	Novus	NBP2-54591
CD16	D1N9L	CST	custom
CD163	EDHu-1	Novus	NB110-40686
Somatostatin	7G5	Novus	NBP2-37447
CD206	poly	R&D	AF2534
CD45	2B11 + PD7/26	Novus	NBP2-34528
Synaptophysin	7H12	Novus	NBP1-47483
HLA-DR	EPR3692	abcam	ab215985
VISTA	D1L2G	CST	custom
IDO	D5I4E	CST	custom
biotinylated Hyaluronan Binding Protein (HABP)	Bollyky Lab Stanford University		custom
HLA-ABC	EMR8-5	BD	565292
TOX	E6I3Q	CST	custom
FOXP3	236A/E7	Invitrogen	14-4777-80
Insulin	K36AC10	Sigma	SAB4200691
Lag3	D2G40	CST	custom
PD-1	D4W2J	CST	custom
PD-L1	E1L3N	CST	custom
CD3	D7A6E	CST	custom
CD4	EPR6855	Abcam	ab181724
CD11c	EP1347Y	AbCam	ab216655
CD56	MRQ-42	Cell Marque	custom
CD45RO	UCH-L1	Santa Cruz	sc-1183
ICOS	D1K2T	CST	custom
Granzyme B	EPR20129-217	Abcam	ab219803
OX40	Ber-ACT35	Biologend	Ber-ACT35
CD138	B-A38	Invitrogen	MA1-10091
CD68	D4B9C	CST	916104
PNAD	MECA-79	Biologend	120801
CD62L	B-8	SCBT	QT 48070

90
91
92

Supplemental Table 4: Antibody Clone Details